var title_f9_59_10160="IDUS showing CHD PV HA";
var content_f9_59_10160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraductal ultrasound showing a normal common hepatic duct, cystic duct, portal vein, and hepatic artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal intraductal ultrasound demonstrating the common hepatic duct (CHD), cystic duct, portal vein (PV), and hepatic artery (HA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Micheal J Levy, Enrique Vazquez-Sequeiros, and Maurits J Wiersema.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10160=[""].join("\n");
var outline_f9_59_10160=null;
var title_f9_59_10161="Typhoid vaccine: Patient drug information";
var content_f9_59_10161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Typhoid vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=see_link\">",
"     see \"Typhoid vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/34/25125?source=see_link\">",
"     see \"Typhoid vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Typhim Vi&reg;;",
"     </li>",
"     <li>",
"      Vivotif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5275259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Typherix&reg;;",
"     </li>",
"     <li>",
"      Typhim Vi&reg;;",
"     </li>",
"     <li>",
"      Vivotif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_typhoid.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11922 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-C04F1AFADF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10161=[""].join("\n");
var outline_f9_59_10161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232369\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5275259\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026004\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/7/25718?source=related_link\">",
"      Typhoid vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/34/25125?source=related_link\">",
"      Typhoid vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_59_10162="Paraaortic node dissection2";
var content_f9_59_10162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cephalad extent of right paraaortic node dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10162=[""].join("\n");
var outline_f9_59_10162=null;
var title_f9_59_10163="Dermatitis herpetiformis direct immunofluorescence";
var content_f9_59_10163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence microscopy in dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence microscopy of a perilesional specimen from a patient with dermatitis herpetiformis demonstrates granular deposits of IgA within the papillary dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10163=[""].join("\n");
var outline_f9_59_10163=null;
var title_f9_59_10164="Gingival infiltration AML";
var content_f9_59_10164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingival infiltration in acute monoblastic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked gingival enlargement affecting both upper and lower gingivae in our patient affected by acute monoblastic leukemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Gallipoli, P, Leach, M. Gingival infiltration in acute monoblastic leukaemia. Br Dental J 2007; 203:507. Copyright &copy; 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10164=[""].join("\n");
var outline_f9_59_10164=null;
var title_f9_59_10165="Ropivacaine: Pediatric drug information";
var content_f9_59_10165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ropivacaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"    see \"Ropivacaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/18/40227?source=see_link\">",
"    see \"Ropivacaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naropin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naropin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Injectable",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"      see \"Ropivacaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia,and condition of patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caudal block: Children (limited data): 2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epidural block (other than caudal block): Children: 1.7 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lumbar epidural surgery: Adults: 75-150 mg (15-30 mL 0.5%); maximum: 200 mg (40 mL 0.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lumbar epidural Cesarean section: Adults: 100-150 mg (20-30 mL 0.5%",
"     <b>",
"      or",
"     </b>",
"     15-20 mL 0.75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Thoracic epidural surgery: Adults: 25-75 mg (5-15 mL 0.5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epidural continuous infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4 months to 7 years (limited data) (Hansen, 2000): 1 mg/kg loading dose followed by 0.4 mg/kg/hour continuous",
"     <b>",
"      epidural",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 10-14 mg loading dose (5-7 mL 0.2%) followed by 12-28 mg/hour (6-14 mL/hour 0.2%) continuous",
"     <b>",
"      epidural",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Major nerve block (eg, brachial plexus block): Adults: 75-300 mg (10-40 mL 0.75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Minor nerve block and infiltration: Adults: 5-200 mg (1-40 mL 0.5%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naropin&reg;: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (20 mL, 30 mL, 100 mL, 200 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer in small incremental doses; when using continuous intermittent catheter techniques, use frequent aspirations before and during the injection to avoid intravascular injection",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature; preservative-free, discard promptly after use; do not mix with alkaline solutions as precipitation will occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Production of local or regional anesthesia for surgery, obstetrical procedures, and for acute pain management: peripheral nerve block, local infiltration, sympathetic block, caudal or epidural block",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ropivacaine may be confused with bupivacaine, rOPINIRole",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F219251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, chest pain, hypo- or hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, dizziness, headache, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, circumoral paresthesia, hypoesthesia, rigors, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema, apnea (usually associated with epidural block in head/neck region), bronchospasm, cardiac arrest, cardiovascular collapse, chondrolysis (continuous intra-articular administration), dyskinesia, hallucinations, hyperthermia, myocardial depression, MI, rash, seizure, syncope, tinnitus, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ropivacaine hydrochloride, any anesthetic of the amide type (eg, bupivacaine, lidocaine, mepivacaine), or any component; not recommended for I.V. regional anesthesia (Bier block)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver disease, impaired cardiovascular function, particularly CHF, hypotension, hypovolemia, heart block, and neurological or psychiatric disorders. Patients treated with class III antiarrhythmics may be at increased risk for additive cardiac effects and should be monitored closely (consider ECG monitoring). For epidural use, it is recommended that a test dose of either a local anesthetic with rapid onset alone or in combination with epinephrine be administered prior to ropivacaine to detect unintentional intravascular or intrathecal injection which would result in systemic toxicity (CNS or cardiovascular)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Convulsions and cardiac arrhythmias, due to systemic toxicity leading to cardiac arrest have been reported, presumably following unintentional I.V. injection; should be administered in small incremental doses; not for use in emergency situations when rapid onset of surgical anesthesia is necessary; not for use for the production of obstetrical paracervical block anesthesia, retrobulbar block, or spinal anesthesia (subarachnoid block); unlike other local anesthetics, administration with epinephrine does not affect onset, duration of action, or the systemic absorption of ropivacaine. Supraclavicular brachial plexus blocks may be associated with a higher frequency of serious adverse effects; major peripheral nerve blocks, often close to large blood vessels pose an increased risk of intravenous systemic absorption due to the proximity and large volume of dosage. Chondrolysis has been reported following continuous intra-articular infusion; intra-articular administration of local anesthetics is not an FDA-approved route of administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fospropofol: May increase the serum concentration of Ropivacaine. Specifically, propofol (the active metabolite of fospropofol) is the entity with the potential to interact with ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propofol: May increase the serum concentration of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal studies. When used for epidural block during labor and delivery, systemically absorbed ropivacaine may cross the placenta, resulting in varying degrees of fetal or neonatal effects (eg, CNS or cardiovascular depression). Fetal or neonatal adverse events include fetal bradycardia (12%), neonatal jaundice (8%), low Apgar scores (3%), fetal distress (2%), neonatal respiratory disorder (3%). Maternal hypotension may also result from systemic absorption. In cases of hypotension, position pregnant woman in left lateral decubitus position to prevent aortocaval compression by the gravid uterus. Epidural anesthesia may prolong the second stage of labor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After epidural or subarachnoid administration: Blood pressure, heart rate, respiration, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of anesthetic action (dependent on dose and route of administration):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural block (100-200 mg): T10 sensory block: 10 minutes (range: 5-13 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural block, Cesarean section (up to 150 mg): T6 sensory block: 11-26 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dependent upon dose and route of administration):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural block (100-200 mg): 4 hours (range: 3-5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural block, Cesarean section (up to 150 mg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sensory block: 1.7-3.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Motor block: 1.4-2.9 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed systemically in a biphasic manner following epidural administration; addition of epinephrine has no affect on the absorption of ropivacaine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (after intravascular infusion):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 2.1-4.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 41 &plusmn; 7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via cytochrome P450 isoenzyme, predominantly CYP1A2 and CYP3A4 (10 metabolites with 2 active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 87% to 98% (epidural)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural: Terminal phase:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 4.9 hours (range: 3-6.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 4.2 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Adults: 1.9 &plusmn; 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration (dose and route dependent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caudal (children): 0.33-2.05 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cesarean section:  14-65 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epidural (adults): 17-97 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 1% to 2% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/18/40227?source=see_link\">",
"      see \"Ropivacaine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary loss of sensation and motor activity in the anesthetized part of the body may occur following proper administration of lumbar epidural anesthesia.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hansen TG, Ilett KF, Lim SI, et al, &ldquo;Pharmacokinetics and Clinical Efficacy of Long-Term Epidural Ropivacaine Infusion in Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2000, 85(3):347-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/59/10165/abstract-text/11103172/pubmed\" id=\"11103172\" target=\"_blank\">",
"        11103172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hansen TG, Ilett KF, Reid C, et al, &ldquo;Caudal Ropivacaine in Infants: Population Pharmacokinetics and Plasma Concentrations,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2001, 94(4):579-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/59/10165/abstract-text/11379676 /pubmed\" id=\"11379676 \" target=\"_blank\">",
"        11379676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lonnqvist PA, Westrin P, Larsson BA, et al, &ldquo;Ropivacaine Pharmacokinetics After Caudal Block in 1-8 Year Old Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2000, 85(4):506-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/59/10165/abstract-text/11064606 /pubmed\" id=\"11064606 \" target=\"_blank\">",
"        11064606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wulf H, Peters C, and Behnke H, &ldquo;The Pharmacokinetics of Caudal Ropivacaine 0.2% in Children. A Study of Infants Aged Less Than 1 Year and Toddlers Aged 1-5 Years Undergoing Inguinal Hernia Repair,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2000, 55(8):757-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/59/10165/abstract-text/10947688/pubmed\" id=\"10947688\" target=\"_blank\">",
"        10947688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12775 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10165=[""].join("\n");
var outline_f9_59_10165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219215\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219216\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061901\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061894\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219198\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219185\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061904\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061897\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061903\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219253\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219251\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061908\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061893\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061892\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219240\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219194\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219196\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219205\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061900\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061891\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061906\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061907\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061899\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=related_link\">",
"      Ropivacaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/18/40227?source=related_link\">",
"      Ropivacaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_59_10166="Pathogenesis MM";
var content_f9_59_10166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    The pathogenesis of multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pathogenesis of multiple myeloma (MM) is complex, but appears to follow a two-step model of progression. First, monoclonal gammopathy of undetermined significance (MGUS) develops as a result of genetic changes, some of which are thought to be the product of an abnormal response to antigenic stimulation. A second event, occurring at random rather than through cumulative damage, results in the accumulation of tumor cells and progression to MM. End organ damage is related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains.",
"    <div class=\"footnotes\">",
"     MGUS: monoclonal gammopathy of undetermined significance; MM: multiple myeloma.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009; 15:5606. Copyright &copy; 2009 American Academy for Cancer Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10166=[""].join("\n");
var outline_f9_59_10166=null;
var title_f9_59_10167="Oxybutynin: Drug information";
var content_f9_59_10167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxybutynin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/47/35574?source=see_link\">",
"    see \"Oxybutynin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/11/40117?source=see_link\">",
"    see \"Oxybutynin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ditropan XL&reg;;",
"     </li>",
"     <li>",
"      Gelnique 3%&trade;;",
"     </li>",
"     <li>",
"      Gelnique&reg;;",
"     </li>",
"     <li>",
"      Oxytrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxybutynin&reg;;",
"     </li>",
"     <li>",
"      Ditropan XL&reg;;",
"     </li>",
"     <li>",
"      Dom-Oxybutynin;",
"     </li>",
"     <li>",
"      Gelnique&reg;;",
"     </li>",
"     <li>",
"      Mylan-Oxybutynin;",
"     </li>",
"     <li>",
"      Novo-Oxybutynin;",
"     </li>",
"     <li>",
"      Nu-Oxybutyn;",
"     </li>",
"     <li>",
"      Oxybutyn;",
"     </li>",
"     <li>",
"      Oxybutynine;",
"     </li>",
"     <li>",
"      Oxytrol&reg;;",
"     </li>",
"     <li>",
"      PHL-Oxybutynin;",
"     </li>",
"     <li>",
"      PMS-Oxybutynin;",
"     </li>",
"     <li>",
"      Riva-Oxybutynin;",
"     </li>",
"     <li>",
"      Uromax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antispasmodic Agent, Urinary",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bladder spasms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 5 mg 2-3 times/day; maximum: 5 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Initial: 5-10 mg once daily, adjust dose in 5 mg increments at weekly intervals; maximum: 30 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Topical gel:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique 3%&trade;: Apply 3 pumps (84 mg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique&reg; 10%: Apply contents of 1 sachet (100 mg/g) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Transdermal:",
"     </i>",
"     Apply one 3.9 mg/day patch twice weekly (every 3-4 days)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/11/40117?source=see_link\">",
"      see \"Oxybutynin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Bladder spasms:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;5 years: Immediate release: 5 mg twice daily; maximum: 5 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years: Extended release: 5 mg once daily; adjust dose in 5 mg increments; maximum: 20 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Immediate release: Initial: 2.5 mg 2-3 times/day; increase cautiously",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Topical gel, transdermal patch:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14266259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (not studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14266260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (not studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique 3%&trade;: 3% (92 g) [contains ethanol; delivers oxybutynin 28 mg/pump actuation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique&reg;: 10% (1 g) [contains ethanol; oxybutynin chloride 100 mg/1 g sachet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxytrol&reg;: 3.9 mg/24 hours (8s) [39 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total oxybutynin 36 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as chloride: 5 mg/5 mL (5 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as chloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as chloride: 5 mg, 10 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ditropan XL&reg;: 5 mg, 10 mg, 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel, transdermal patch",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16057118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oxytrol&reg; for Women: FDA approved January 2013; availability anticipated in the fall of 2013. Oxytrol&reg; for Women is an over-the-counter (OTC) transdermal patch indicated for the treatment of overactive bladder.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F204672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer without regard to meals. Extended release tablets must be swallowed whole with liquid; do not crush, divide, or chew; take at approximately the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical gel: For topical use only. Apply to clean, dry, intact skin on abdomen, thighs, or upper arms/shoulders. Wash hands after use. Cover treated area with clothing after gel has dried to prevent transfer of medication to others. Do not bathe, shower, or swim until 1 hour after gel applied. Do not apply to recently shaved skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique 3%&trade;: Prior to initial use, press pump 4 times to prime pump; discard any gel dispensed from pump during priming. Rotate application sites to avoid skin irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelnique&reg; 10%: Rotate site; do not apply to same site on consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal: Apply to clean, dry skin on abdomen, hip, or buttock. Select a new site for each new system (avoid reapplication to same site within 7 days).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antispasmodic for neurogenic bladder (urgency, frequency, leakage, urge incontinence, dysuria); extended release formulation also indicated for treatment of symptoms associated with detrusor overactivity due to a neurological condition (eg, spina bifida)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oxybutynin may be confused with OxyCONTIN&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ditropan may be confused with Detrol&reg;, diazepam, Diprivan&reg;, dithranol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4% to 17%), somnolence (2% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (29% to 71%; dose related), constipation (7% to 15%), nausea (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (sinus; 1% to &lt;5%), blood pressure change (increased/decreased; 1% to &lt;5%), chest pain (1% to &lt;5%), edema (1% to &lt;5%), flushing (1% to &lt;5%), palpitation (1% to &lt;5%), peripheral edema (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6% to 10%), nervousness (1% to 7%), pain (1% to 7%), insomnia (1% to 6%), confusion (1% to &lt;5%), depression (1% to &lt;5%), fatigue (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dry skin (1% to &lt;5%), pruritus (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention (1% to &lt;5%), hyperglycemia (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1% to 9%), dyspepsia (5% to 7%), abdominal pain (1% to &lt;5%), abnormal taste (1% to &lt;5%), dry throat (1% to &lt;5%), dysphagia (1% to &lt;5%), eructation (1% to &lt;5%), flatulence (1% to &lt;5%), gastrointestinal reflux disease (1% to &lt;5%), vomiting (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary hesitation (9%), urinary tract infection (5% to 7%), urinary retention (6%), cystitis (1% to &lt;5%), dysuria (1% to &lt;5%), pollakiuria (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1% to 7%), arthralgia (1% to &lt;5%), back pain (1% to &lt;5%), extremity pain (1% to &lt;5%), flank pain (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (1% to 10%), dry eyes (3% to 6%), eye irritation (1% to &lt;5%), keratoconjunctivitis sicca (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma (1% to &lt;5%), bronchitis (1% to &lt;5%), cough (1% to &lt;5%), hoarseness (1% to &lt;5%), nasal congestion (1% to &lt;5%), nasal dryness (1% to &lt;5%), nasopharyngitis (1% to &lt;5%), pharyngolaryngeal pain (1% to &lt;5%), sinus congestion (1% to &lt;5%), upper respiratory tract infection (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fungal infection (1% to &lt;5%), thirst (1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, anorexia, cycloplegia, dysphonia, GI motility decreased, glaucoma, hallucinations, hypersensitivity reactions, impotence, lactation suppression, memory impairment, mydriasis, psychotic disorder, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, seizures, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Topical gel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction (4% to 14%; includes dermatitis, erythema, irritation, pain, papules, pruritus, rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 3%), fatigue (2%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Gastroenteritis (2%), constipation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (5% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis (4%), blurred vision (&lt;2%), dry eyes (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Transdermal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Local: Application site reaction (17%), pruritus (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (4% to 10%), constipation (3%), diarrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Erythema (6% to 8%), rash (3%), vesicles (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision changes (3%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Cardiac arrhythmia, cycloplegia, hallucinations, impotence, lactation suppressed, myocarditis, seizure, sweating decreased, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxybutynin or any component of the formulation; patients with or at risk for uncontrolled narrow-angle glaucoma, urinary retention, gastric retention or conditions with severely decreased GI motility",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Cases of angioedema have been reported with oral oxybutynin; some cases have occurred after a single dose.  Discontinue immediately if develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (eg, agitation, confusion, hallucinations, somnolence) which may require dose reduction or discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat prostration: May increase the risk of heat prostration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autonomic neuropathy: Use with caution in patients with autonomic neuropathy; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with CAD, heart failure, hypertension, and/or cardiac arrhythmias; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Use with caution in patients with dementia treated with cholinesterase inhibitors; may aggravate symptoms of disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disorders: Use with caution in patients with ulcerative colitis, intestinal atony, gastroesophageal reflux or with medications that may exacerbate esophagitis (eg, bisphosphonates). May decrease GI motility; in patients with ulcerative colitis, use may increase risk of paralytic ileus or toxic megacolon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with treated angle-closure glaucoma; may exacerbate condition; use is contraindicated with uncontrolled narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; due to limited experience.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hiatal hernia: Use with caution in patients with hiatal hernia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture; may cause urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; due to limited experience. Use caution with bladder outflow obstruction; may increase risk of urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Medication associated with potent anticholinergic properties which may be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) (Beers Criteria ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release formulation: The extended release formulation consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract has been associated with symptoms of obstruction (rare).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical gel:  To minimize transferring medication to others, cover treatment area with clothing after gel has dried. Discontinue use if skin irritation occurs. Contains ethanol; do not expose to open flame or smoking until gel has dried.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F204690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Use ethanol with caution (may increase CNS depression and toxicity). Watch for sedation.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F204678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppression of lactation has been reported.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F204679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food causes a slight delay in the absorption of the oral solution and bioavailability is increased by ~25%. Absorption of the extended release tablet is not affected by food. May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F204676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Gelnique Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 (28) %(mg/act) (92 g): $211.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1 g): $8.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, twice-weekly",
"     </b>",
"     (Oxytrol Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.9 mg/24 hrs (4): $0.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Oxybutynin Chloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (473 mL): $38.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Ditropan XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $547.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $548.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $561.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Oxybutynin Chloride ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $328.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $328.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $336.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxybutynin Chloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $56.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incontinence episodes, postvoid residual (PVR)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F204680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ao Ning (CL);",
"     </li>",
"     <li>",
"      Butyn (PK);",
"     </li>",
"     <li>",
"      Cystrin (GB);",
"     </li>",
"     <li>",
"      Delifon (CO);",
"     </li>",
"     <li>",
"      Ditropan (AR, AT, AU, BE, CH, CZ, FI, FR, GB, GR, HN, HU, IT, KP, LU, PL, PT, SE, TW);",
"     </li>",
"     <li>",
"      Diutropan (TH);",
"     </li>",
"     <li>",
"      Dridase (DE, NL);",
"     </li>",
"     <li>",
"      Driptane (EE, PH, RU);",
"     </li>",
"     <li>",
"      Frenurin (BR);",
"     </li>",
"     <li>",
"      Gradual (UY);",
"     </li>",
"     <li>",
"      Inprax (MX);",
"     </li>",
"     <li>",
"      Kentera (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Kentera Patch (GB, IE);",
"     </li>",
"     <li>",
"      Lenditro (ZA);",
"     </li>",
"     <li>",
"      Lyrinel (IL, MX, TH);",
"     </li>",
"     <li>",
"      Lyrinel Oros SR (KP);",
"     </li>",
"     <li>",
"      Lyrinel XL (GB);",
"     </li>",
"     <li>",
"      Mutum (EC);",
"     </li>",
"     <li>",
"      Mutum CR (EC);",
"     </li>",
"     <li>",
"      Nefryl (MX);",
"     </li>",
"     <li>",
"      Novitropan (IL);",
"     </li>",
"     <li>",
"      Obutin (SG);",
"     </li>",
"     <li>",
"      Odranal (CN);",
"     </li>",
"     <li>",
"      Oxyban (TW);",
"     </li>",
"     <li>",
"      Oxytrol (AU, NZ);",
"     </li>",
"     <li>",
"      Pollakisu (JP);",
"     </li>",
"     <li>",
"      Reteven (PE, VE);",
"     </li>",
"     <li>",
"      Tavor (MX);",
"     </li>",
"     <li>",
"      Tropan (IN);",
"     </li>",
"     <li>",
"      Urihexal (ZA);",
"     </li>",
"     <li>",
"      Uroflax (PY);",
"     </li>",
"     <li>",
"      Uropan (TR);",
"     </li>",
"     <li>",
"      Uroxal (HU);",
"     </li>",
"     <li>",
"      Voxytane (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Direct antispasmodic effect on smooth muscle, also inhibits the action of acetylcholine on smooth muscle (exhibits",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      5",
"     </sub>",
"     the anticholinergic activity of atropine, but is 4-10 times the antispasmodic activity); does not block effects at skeletal muscle or at autonomic ganglia; increases bladder capacity, decreases uninhibited contractions, and delays desire to void, therefore, decreases urgency and frequency",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-10 hours (up to 24 hours for extended release oral formulation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and well absorbed; Transdermal: High",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      d",
"     </sub>",
"     : 193 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99% primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; Oral: High first-pass metabolism; forms active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: ~6%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: ~2 hours (parent drug), 7-8 hours (metabolites); Oral: Immediate release: ~2-3 hours; Extended release: ~13 hours; Transdermal: 30-64 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Immediate release: ~60 minutes; Extended release: 4-6 hours; Transdermal: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine, as metabolites and unchanged drug (&lt;0.1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/59/10167/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katz IR, Sands LP, Bilker W, et al, \"Identification of Medications That Cause Cognitive Impairment in Older People: The Case of Oxybutynin Chloride,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      ,1998, 46(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/59/10167/abstract-text/9434659/pubmed\" id=\"9434659\" target=\"_blank\">",
"        9434659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9728 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AA8FF843F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10167=[""].join("\n");
var outline_f9_59_10167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204694\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204695\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204735\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204698\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204716\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204699\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14266259\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14266260\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204653\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057118\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204672\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204671\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204742\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204733\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204675\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204657\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204730\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204662\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204690\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204677\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204702\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204678\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204679\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204676\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204667\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204680\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204656\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204674\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9728\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9728|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/47/35574?source=related_link\">",
"      Oxybutynin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/11/40117?source=related_link\">",
"      Oxybutynin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_59_10168="Extracorporeal shock wave lithotripsy for pancreatic stones";
var content_f9_59_10168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extracorporeal shock wave lithotripsy for pancreatic stones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10168/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10168/contributors\">",
"     Myriam Delhaye, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10168/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10168/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/59/10168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of human calculi by extracorporeal shock wave lithotripsy (ESWL) was first used in patients for the treatment of kidney stones in 1980 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, this technique has been applied to gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/2\">",
"     2",
"    </a>",
"    ] and pancreatic stones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of pancreatic stones using ESWL will be reviewed here. The treatment of chronic pancreatitis, electrohydraulic lithotripsy, and laser lithotripsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE OF PANCREATIC STONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic duct stones are found in approximately 22 to 60 percent of patients with chronic pancreatitis (CP) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/4\">",
"     4",
"    </a>",
"    ]. The stones can lead to obstruction of the outflow of pancreatic secretions, causing increased intraductal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/5\">",
"     5",
"    </a>",
"    ]. Because the pancreas is relatively noncompliant, the rise in intraductal pressure can induce tissue hypertension and ischemia, which may be a major factor causing pain in patients with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/6\">",
"     6",
"    </a>",
"    ]. This hypothesis is supported by the observation that symptoms may improve following pancreatic duct drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extraction of pancreatic duct stones has usually been attempted during endoscopic retrograde cholangiopancreatography (ERCP). However, successful stone extraction during ERCP depends upon the size and location of the stones and may not be possible if strictures are present or pancreatic stones have become embedded in the ductal system. As a result, a method of stone disruption prior to endoscopic extraction could be helpful. ESWL leads to the fragmentation of pancreatic stones, which has improved the results of endoscopic therapy and may have additional indications in the treatment of patients with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LITHOTRIPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lithotripsy works by concentrating focused shock waves (SWs) on stones, which causes their disruption. Shock waves can be generated by three methods:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spark discharge (Dornier system)",
"     </li>",
"     <li>",
"      Piezoelectric elements (Wolf system)",
"     </li>",
"     <li>",
"      Electromagnetic deflection of a metal membrane (Siemens system)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    SW generation takes place in degassed water. The shock waves are focused by reflection of the primary wave, arraying of the piezoceramic elements on a hemispherical disk, or by an acoustic lens. SWs are directed into the body via a water cushion or a water basin.",
"   </p>",
"   <p>",
"    The stones must be localized using ultrasound (US) or x-ray prior to lithotripsy. Application of several hundred to several thousand SWs to the calculus in a focal area results in gradual disintegration of the stone. Disintegration results from the rapidly rising pressures (up to 500 to 1000 bar) within the focal area [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other forms of pancreatic stone lithotripsy have been reported in small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The techniques involve disruption of pancreatic stones by intraductal mechanical, electrohydraulic, or pulsed-dye laser lithotripsy during ERCP. These methods probably offer no advantage over ESWL, which is simple to perform, has high efficacy and has a low complication rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ESWL in the management of patients with chronic pancreatitis is evolving. The technique is not widely available, particularly in the United States, and its efficacy compared to other methods of treatment has not been established in randomized controlled trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .) However, a meta-analysis including a total of 588 patients found that ESWL was effective in relieving main pancreatic duct obstruction and alleviating pain in chronic calcifying pancreatitis, most often in combination with endoscopic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESWL for pancreatic stones is indicated for patients with all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent attacks of pancreatic pain",
"     </li>",
"     <li>",
"      Moderate to marked changes in the pancreatic ductal system",
"     </li>",
"     <li>",
"      Obstructing ductal stones (calcified or radiolucent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost all stones are amenable to therapy because their biochemical composition consists of 95 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    on a protein matrix. In our experience, approximately 44 percent of patients with chronic pancreatitis were eligible for ESWL [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique is optimally suited for patients who have a dilated main pancreatic duct that contains a single stone but has no stricture. However, patients with relatively unfavorable characteristics (such as those with multiple stones, pancreatic duct strictures, or small pseudocysts, or those who continue to drink alcohol) may also benefit from ESWL (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Clinical results'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is contraindicated in patients who have coagulation disorders, in women who are pregnant, in patients with implanted cardiac pacemakers or defibrillators, and in patients who have bone, calcified aneurysms, or lung tissue in the SW path.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Stone localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate visualization of pancreatic and surrounding anatomy is essential prior to ESWL. We usually accomplish this by obtaining good quality plain films of the pancreatic area in left and right oblique positions, as well as a magnetic resonance cholangiopancreatography (MRCP) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    injection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/14\">",
"     14",
"    </a>",
"    ]. In centers in which MRCP is unavailable, a CT scan with and without intravenous contrast can also demonstrate pancreatic ductal obstruction related to pancreatic stones.",
"   </p>",
"   <p>",
"    In the majority of patients, a two-dimensional radiologic targeting system is required during lithotripsy because ultrasound localization of pancreatic stones is insufficiently precise. In one study, for example, the position of the stone was monitored successfully in only 14 percent of patients treated with a piezoelectric lithotriptor featuring an integrated combination of an ultrasound and radiographic stone localization system [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Localization by ultrasound may be better when the main pancreatic duct is dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/16\">",
"     16",
"    </a>",
"    ]. The median stone size and pancreatic duct size was 12 mm in one report that relied exclusively on ultrasound targeting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/17\">",
"     17",
"    </a>",
"    ]. For very small stones or radiolucent stones, visualization can be improved by instillation of contrast medium through a nasopancreatic catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESWL can be carried out with conscious sedation, epidural anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/18\">",
"     18",
"    </a>",
"    ], or general anesthesia. General anesthesia may be particularly helpful in patients undergoing ESWL and therapeutic ERCP during the same session. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities have recommended antibiotic prophylaxis for ESWL [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. We, however, only use antibiotic prophylaxis before ERCP when there is cholestasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Application of shock waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients are positioned so that the stones are separated from the spine (slight left or right lateral decubitus), with SWs entering the body from the ventral side [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,15,16,19-23\">",
"     9,15,16,19-23",
"    </a>",
"    ]. Some lithotriptor devices require that the SWs enter from the dorsal side [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/17,24\">",
"     17,24",
"    </a>",
"    ] or obliquely [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SWs should be focused first on the most distally located stone and then on the other calculi proceeding from the head to the tail. This allows drainage of the fragments downwards through the papilla. A total of 3000 to 5000 SWs using the highest possible energy level (0.54",
"    <span class=\"nowrap\">",
"     mJ/mm-2)",
"    </span>",
"    are usually delivered in one treatment session, which lasts approximately 45 to 60 minutes. When ERCP immediately follows the ESWL session, the energy level of the SW is reduced to a maximum level of 0.33 to 0.37",
"    <span class=\"nowrap\">",
"     mJ/mm-2",
"    </span>",
"    to avoid duodenal edema and erosions, which might impair further endoscopic treatment.",
"   </p>",
"   <p>",
"    SWs can be triggered by breathing (when the stone is moving out of the focal zone during breathing)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by the electrocardiogram (during the refractory period). This is particularly helpful in patients who have a history of cardiac arrhythmias, as ventricular extrasystoles can be observed during lithotripsy. In these patients, SWs should be delivered only during the refractory period to avoid possible ventricular arrhythmias.",
"   </p>",
"   <p>",
"    Repeat ESWL may be required if stones have incompletely disintegrated, which is often the case in patients with large or multiple stones. The reported mean number of treatment sessions required to complete lithotripsy has ranged from 1.3 to 6.0 per patient in most reports [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,15,18,19,22,23,26-28\">",
"     9,15,18,19,22,23,26-28",
"    </a>",
"    ], though one series reported a median of 13 sessions (range 2 to 74) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Need for ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, therapeutic ERCP is usually required within a few hours of ESWL to remove stone fragments. However, in other centers, successful spontaneous passage of the residual fragmented stones has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/21,27,28\">",
"     21,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'ESWL monotherapy compared to ESWL combined with endoscopic drainage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a series from Japan, 24 of 32 patients (75 percent) with stones in the main pancreatic duct achieved spontaneous stone clearance following ESWL applied once or twice per week [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the high rates of spontaneous stone clearance seen in this study may be explained by the selection of patients without severe main pancreatic duct strictures (22 out of 32) and with good residual exocrine function (only 2 patients out of 32 (6 percent) presented steatorrhea) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/21\">",
"     21",
"    </a>",
"    ]. Based on the available data, we suggest allowing spontaneous passage of the stone fragments only in patients without an associated tight stricture and with good residual exocrine function.",
"   </p>",
"   <p>",
"    On the other hand, many authorities advocate that pancreatic sphincterotomy should be performed PRIOR to ESWL to facilitate stone passage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/15,17,19,20,22,29\">",
"     15,17,19,20,22,29",
"    </a>",
"    ]. Pancreatic sphincterotomy is usually performed after biliary sphincterotomy to separate the two orifices. Placement of a nasopancreatic tube with its tip proximal to the unfragmented stone increases the efficacy of ESWL and may permit stone passage when the tube is perfused during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,23\">",
"     9,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stone extraction during ERCP can be accomplished with a mini-Dormia basket using the \"rotation-perfusion\" technique, which consists of sweeping the basket along the main pancreatic duct with a rotary motion while injecting saline solution to flush out fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/30\">",
"     30",
"    </a>",
"    ]; the Fogarty balloon catheter is less efficient than the Dormia basket. A 6-Fr nasopancreatic catheter should be left in place for one or two days and perfused with an isotonic saline solution (one liter every 24 hours) to eliminate stone fragments.",
"   </p>",
"   <p>",
"    Additional therapeutic options may be required in patients who have a pancreatic stricture or other complications of chronic pancreatitis, such as a pseudocyst or biliary stricture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .) In patients with a dominant dorsal duct (complete or incomplete pancreas divisum), pancreatic ductal drainage can be accomplished through the minor papilla. This was required in approximately 20 percent of our patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,23\">",
"     9,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESWL permits nonsurgical clearance of pancreatic stones much larger than those traditionally amenable to endoscopic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/3,9,24,27,31,32\">",
"     3,9,24,27,31,32",
"    </a>",
"    ]. Increasing experience with this technique has improved its success [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/30\">",
"     30",
"    </a>",
"    ]. In a multivariate analysis of 70 patients with ductal stones who underwent pancreatic sphincterotomy and attempted stone removal, the availability of ESWL was the only independent factor influencing the technical results of endoscopic management [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Technical results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disintegration of a calcified pancreatic stone can be considered successful when one of the following findings is seen on plain films following ESWL:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A decrease in the radiographic density of the stone",
"     </li>",
"     <li>",
"      An increase in the stone surface area",
"     </li>",
"     <li>",
"      Heterogeneity of the stone, which appears as powder-like material filling the pancreatic and the surrounding secondary ducts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes should be accompanied by relief of ductal obstruction demonstrated by successful deep cannulation of the main pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9\">",
"     9",
"    </a>",
"    ]. Using this definition, the success rate of fragmentation has been approximately 76 to 100 percent in most series, regardless of the SW system used (",
"    <a class=\"graphic graphic_table graphicRef60050 \" href=\"UTD.htm?10/60/11213\">",
"     table 1",
"    </a>",
"    ). However, in two reports involving a total of 128 patients, ESWL was considered to be technically successful in only 54 and 60 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/17,26\">",
"     17,26",
"    </a>",
"    ]. The high technical failure rate in these series was probably related to the exclusive use of ultrasound to localize stones.",
"   </p>",
"   <p>",
"    In most reports, successful fragmentation and stone clearance has not correlated with the initial size or the number of main pancreatic duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/21,22,32\">",
"     21,22,32",
"    </a>",
"    ]. However, at least two studies showed successful treatment was more frequent in patients with solitary stones. In one study, stone clearance occurred in 74 percent of those with solitary stones versus 43 percent in those with multiple stones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/26\">",
"     26",
"    </a>",
"    ]. In another study, complete removal of stones was achieved more frequently in patients with a single stone (73 versus 48 percent for multiple stones) and without a main pancreatic duct stricture (67 versus 44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients studied required endoscopic extraction of fragments after ESWL for complete clearance from the ductal system except, as mentioned above, in one study in which complete clearance of the main pancreatic duct stones was obtained spontaneously in 75 percent of patients (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Need for ERCP'",
"    </a>",
"    above)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decompression of the pancreatic duct is obtained in 70 to 96 percent of the patients treated with ESWL followed by endoscopic ductal drainage procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,16,18,23,24\">",
"     9,16,18,23,24",
"    </a>",
"    ]. Furthermore, disappearance of communicating cysts and pseudocysts has been observed in 74 percent of these cases, mainly with small cysts located in the head of the pancreas. This presumably occurs as a result of reduced ductal pressure due to alleviation of the distal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have shown that ESWL is effective at both relieving pain in patients with chronic pancreatitis and at improving pancreatic exocrine (but not necessarily endocrine) function. However, the variable natural history of chronic pancreatitis complicates the assessment of treatments aimed at relieving symptoms. In one series, for example, 85 percent of 141 patients with chronic calcific pancreatitis obtained pain relief after a median time of 4.5 years, and the rates of pain relief were similar in those who underwent surgery and in those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pain relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic success of ESWL has been associated with clinical improvement. Studies have found that complete or partial pain relief following ESWL was achieved in 62 to 91 percent of patients during a mean follow-up ranging from 7 to 77 months (",
"    <a class=\"graphic graphic_table graphicRef71445 \" href=\"UTD.htm?26/35/27197\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,15-17,21,23,26,27,29,32,34\">",
"     9,15-17,21,23,26,27,29,32,34",
"    </a>",
"    ]. Immediate relief of or improvement in pain was associated with successful decompression of the main pancreatic duct (as suggested by decrease in its diameter or stone clearance) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,17,24,30\">",
"     9,17,24,30",
"    </a>",
"    ]. However, complete stone clearance was not required for symptom relief. A considerable number of patients gained weight due to a reduction in postprandial pain attacks, improvement in pancreatic function, or both.",
"   </p>",
"   <p>",
"    Multiple studies have looked for factors associated with pain relapse, with variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number and location of stones, the presence of a stricture, or continued alcohol use did not appear to be associated with recurrent pain in many reports [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,15,29\">",
"       9,15,29",
"      </a>",
"      ]. This suggests that ESWL can be attempted in patients with these clinical characteristics.",
"     </li>",
"     <li>",
"      In a randomized trial, the presence of obstructing calcifications in the head of the pancreas was independently associated with the absence of pain relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series with long follow-up (14.4 years), not smoking was associated with fewer hospital admissions for pain treatment, while alcohol abuse increased the risk for diabetes, steatorrhea, and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/36\">",
"       36",
"      </a>",
"      ]. Smoking cessation was also associated with improved outcomes in a second study [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report found that pain improvement was associated with nonalcoholic chronic pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Independent predictors of pain relapse at long-term follow-up in another report were a high frequency of pain attacks before treatment (more than or at least two pain attacks during the two months before treatment), a long duration of disease before treatment, and the presence of a nonpapillary stenosis of the main pancreatic duct [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/30\">",
"       30",
"      </a>",
"      ]. These findings suggest that ESWL with endoscopic therapy should be performed as early as possible in the course of chronic pancreatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pancreatic endocrine and exocrine function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early ductal decompression of the main pancreatic duct may help prevent further fibrosis, which can lead to pancreatic insufficiency. In addition, it may improve pancreatic function in patients who have already developed pancreatic insufficiency.",
"   </p>",
"   <p>",
"    Studies have shown that pancreatic exocrine function improves more often after treatment than pancreatic endocrine function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,17,21,27\">",
"     9,17,21,27",
"    </a>",
"    ]. In those studies, pancreatic endocrine function remained largely unaffected, except in a few patients. In our long-term studies, we have also observed that endoscopic ductal drainage (including ESWL) can delay the development of pancreatic exocrine insufficiency by about 10 years compared to the natural history of chronic pancreatitis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/36\">",
"     36",
"    </a>",
"    ]. By contrast, it did not change the development of diabetes in the course of chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appearance of de novo steatorrhea has been associated with a long duration of symptomatic ductal obstruction, whereas the development of de novo diabetes was only related to alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/36\">",
"     36",
"    </a>",
"    ]. These findings are supported by another study in which pancreatic exocrine function deteriorated more significantly in the group of patients with initial incomplete stone removal, whereas the frequency of diabetes was higher in patients with alcoholic pancreatitis and in those who continued drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Stone recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most series, recurrent pain attacks were usually related to stone migration or recurrence, progressive stricturing of the main pancreatic duct, or pancreatic stent obstruction or dislodgement. The majority of these patients could be managed successfully by endoscopy or a combination of endoscopy and ESWL [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,15,23,27,28,32\">",
"     9,15,23,27,28,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a representative series, after achieving complete clearance of the main pancreatic duct, stone recurrence was found in 48 percent of patients at a mean follow-up of 7.4 months. The median \"stone-free survival time\" calculated with the Kaplan-Meier method was 18.5 months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/32\">",
"       32",
"      </a>",
"      ]. The technical and clinical success rates for treatment of recurrent stones were comparable with those of initial therapy.",
"     </li>",
"     <li>",
"      In another series, stone recurrence developed in 22 percent of patients, with a mean time to recurrence of 25 months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/27\">",
"       27",
"      </a>",
"      ]. The presence of a ductal stricture was associated with stone recurrence (a finding that we have also observed).",
"     </li>",
"     <li>",
"      In a long-term study, approximately one-third of patients experienced pain relapses during a mean follow-up period of 77 months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/28\">",
"       28",
"      </a>",
"      ]. All such patients had intraductal pancreatic stones. Pain relapse occurred significantly more frequently in patients with incomplete removal of stones after the initial therapy (HR of 3.7) and in those with a main pancreatic duct stricture (HR of 3.4). Both factors were significant risk factors for pain relapse on multivariate analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ESWL monotherapy compared to ESWL combined with endoscopic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have directly compared ESWL monotherapy to ESWL combined with endoscopic drainage, but the data available suggest that the results are similar for the two approaches.",
"   </p>",
"   <p>",
"    A randomized controlled trial compared ESWL alone to ESWL and endoscopic drainage of the main pancreatic duct for treatment of pain in chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/35\">",
"     35",
"    </a>",
"    ]. In 55 patients with uncomplicated calcified chronic pancreatitis, ESWL alone (n=26) was found to be a safe and effective treatment. No significant differences in the outcome of pancreatic pain were reported when ESWL alone was compared with the combination of endoscopy with ESWL treatment (n=29). The patients did not undergo ERCP prior to ESWL, so there was no grading of any associated main pancreatic duct stricture(s). However, a similar decrease in the main pancreatic duct diameter was reported one month after treatment.",
"   </p>",
"   <p>",
"    In another report of 555 patients, ESWL was applied as monotherapy in 57 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/27\">",
"     27",
"    </a>",
"    ]. Although technical or clinical results were not directly compared between patients treated with ESWL alone or with ESWL and endotherapy, spontaneous stone clearance after ESWL alone was obtained in 70 percent of patients. This rate was similar to the overall complete ductal clearance rate of 73 percent for the series as a whole [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the above findings, the advantages of treatment with ESWL alone (noninvasiveness, efficiency, innocuousness, and low cost) have to be considered when choosing the initial therapeutic option in selected patients. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Patient selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Need for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic surgery is required in 1.4 to 20 percent of patients after technical failure of stone disintegration or endoscopic ductal drainage, or for complications of pancreatitis beyond the capability of endoscopic management. Later surgery may also be indicated for definitive biliary drainage (hepaticojejunostomy) or for pancreatic ductal drainage (pancreaticojejunostomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of chronic pancreatitis\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe complications, such as organ damage or acute pancreatitis, are rare following ESWL. Overall morbidity is related primarily to the associated endoscopic procedures and is generally easily controlled with medical treatment. No procedural or hospital mortality has been reported in the large published series (",
"    <a class=\"graphic graphic_table graphicRef50292 \" href=\"UTD.htm?43/47/44796\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/9,15-18,21,23,24,31,37\">",
"     9,15-18,21,23,24,31,37",
"    </a>",
"    ], except for one case of fatal acute cholangitis reported in a large multicenter Japanese survey of 555 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other findings related to ESWL that are of unclear clinical significance include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small series of 13 patients with pancreatic stones treated by ESWL and investigated before and after lithotripsy, there was a transient increase in serum lipase, mild hemolysis, and an isolated increase in serum LDH 5 isoenzyme, suggesting granulocyte damage [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10168/abstract/38\">",
"       38",
"      </a>",
"      ]. All of these effects were without clinical significance and reversed after 24 hours.",
"     </li>",
"     <li>",
"      Petechiae are regularly noted on the skin at the area of SW penetration.",
"     </li>",
"     <li>",
"      Erosions in the gastric antrum, sometimes hemorrhagic, have been observed when endoscopy has been performed immediately following ESWL, but again, without clinical consequences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extracorporeal shock wave lithotripsy (ESWL) can be considered as a first-line approach in patients with painful chronic pancreatitis associated with obstructive ductal stones (calcified or radiolucent), inducing upstream dilatation of the main pancreatic duct, regardless of the etiology of the chronic pancreatitis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best fragmentation rates (approximately 90 percent) are obtained when a fluoroscopic targeting system is used to focus on the stones, regardless of the shock wave delivery system used. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Technical results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As a general rule, stone fragmentation by ESWL is followed by endoscopic ductal drainage using pancreatic sphincterotomy, fragmented stone extraction, and pancreatic stenting in the case of a ductal stricture. However, in selected patients with uncomplicated calcified chronic pancreatitis, ESWL without endoscopic ductal drainage may be an option. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Need for ERCP'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'ESWL monotherapy compared to ESWL combined with endoscopic drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After completion of endoscopic pancreatic ductal drainage, definitive pain relief can be expected in about two-thirds of patients at long-term follow-up. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pain relief'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best clinical results are seen in patients who do not smoke and in patients who receive early treatment in the course of their chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pain relief'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/1\">",
"      Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. Lancet 1980; 2:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/2\">",
"      Sauerbruch T, Delius M, Paumgartner G, et al. Fragmentation of gallstones by extracorporeal shock waves. N Engl J Med 1986; 314:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/3\">",
"      Sauerbruch T, Holl J, Sackmann M, et al. Disintegration of a pancreatic duct stone with extracorporeal shock waves in a patient with chronic pancreatitis. Endoscopy 1987; 19:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/4\">",
"      Drake DH, Fry WJ. Ductal drainage for chronic pancreatitis. Surgery 1989; 105:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/5\">",
"      Bradley EL 3rd. Pancreatic duct pressure in chronic pancreatitis. Am J Surg 1982; 144:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/6\">",
"      Reber HA, Karanjia ND, Alvarez C, et al. Pancreatic blood flow in cats with chronic pancreatitis. Gastroenterology 1992; 103:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/7\">",
"      Schneider MU, Lux G. Floating pancreatic duct concrements in chronic pancreatitis. Pain relief by endoscopic removal. Endoscopy 1985; 17:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/8\">",
"      Sherman S, Lehman GA, Hawes RH, et al. Pancreatic ductal stones: frequency of successful endoscopic removal and improvement in symptoms. Gastrointest Endosc 1991; 37:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/9\">",
"      Delhaye M, Vandermeeren A, Baize M, Cremer M. Extracorporeal shock-wave lithotripsy of pancreatic calculi. Gastroenterology 1992; 102:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/10\">",
"      Sauerbruch T. Extracorporeal shock wave lithotripsy. Digestion 1997; 58 Suppl 1:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/11\">",
"      Freeman ML. Mechanical lithotripsy of pancreatic duct stones. Gastrointest Endosc 1996; 44:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/12\">",
"      Neuhaus H, Hoffmann W, Classen M. Laser lithotripsy of pancreatic and biliary stones via 3.4 mm and 3.7 mm miniscopes: first clinical results. Endoscopy 1992; 24:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/13\">",
"      Guda NM, Partington S, Freeman ML. Extracorporeal shock wave lithotripsy in the management of chronic calcific pancreatitis: a meta-analysis. JOP 2005; 6:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/14\">",
"      Matos C, Metens T, Devi&egrave;re J, et al. Pancreatic duct: morphologic and functional evaluation with dynamic MR pancreatography after secretin stimulation. Radiology 1997; 203:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/15\">",
"      Schneider HT, May A, Benninger J, et al. Piezoelectric shock wave lithotripsy of pancreatic duct stones. Am J Gastroenterol 1994; 89:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/16\">",
"      Johanns W, Jakobeit C, Greiner L, Janssen J. Ultrasound-guided extracorporeal shock wave lithotripsy of pancreatic ductal stones: six years' experience. Can J Gastroenterol 1996; 10:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/17\">",
"      Brand B, Kahl M, Sidhu S, et al. Prospective evaluation of morphology, function, and quality of life after extracorporeal shockwave lithotripsy and endoscopic treatment of chronic calcific pancreatitis. Am J Gastroenterol 2000; 95:3428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/18\">",
"      Ong WC, Tandan M, Reddy V, et al. Multiple main pancreatic duct stones in tropical pancreatitis: safe clearance with extracorporeal shockwave lithotripsy. J Gastroenterol Hepatol 2006; 21:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/19\">",
"      van der Hul R, Plaisier P, Jeekel J, et al. Extracorporeal shock-wave lithotripsy of pancreatic duct stones: immediate and long-term results. Endoscopy 1994; 26:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/20\">",
"      Martin RF, Hanson BL, Bosco JJ, et al. Combined modality treatment of symptomatic pancreatic ductal lithiasis. Arch Surg 1995; 130:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/21\">",
"      Ohara H, Hoshino M, Hayakawa T, et al. Single application extracorporeal shock wave lithotripsy is the first choice for patients with pancreatic duct stones. Am J Gastroenterol 1996; 91:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/22\">",
"      Schreiber F, Gurakuqi GC, Pristautz H, et al. Sonographically-guided extracorporeal shockwave lithotripsy for pancreatic stones in patients with chronic pancreatitis. J Gastroenterol Hepatol 1996; 11:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/23\">",
"      Costamagna G, Gabbrielli A, Mutignani M, et al. Extracorporeal shock wave lithotripsy of pancreatic stones in chronic pancreatitis: immediate and medium-term results. Gastrointest Endosc 1997; 46:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/24\">",
"      Sauerbruch T, Holl J, Sackmann M, Paumgartner G. Extracorporeal lithotripsy of pancreatic stones in patients with chronic pancreatitis and pain: a prospective follow up study. Gut 1992; 33:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/25\">",
"      Grimm H, Meyer WH, Nam VC, Soehendra N. New modalities for treating chronic pancreatitis. Endoscopy 1989; 21:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/26\">",
"      Adamek HE, Jakobs R, Buttmann A, et al. Long term follow up of patients with chronic pancreatitis and pancreatic stones treated with extracorporeal shock wave lithotripsy. Gut 1999; 45:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/27\">",
"      Inui K, Tazuma S, Yamaguchi T, et al. Treatment of pancreatic stones with extracorporeal shock wave lithotripsy: results of a multicenter survey. Pancreas 2005; 30:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/28\">",
"      Tadenuma H, Ishihara T, Yamaguchi T, et al. Long-term results of extracorporeal shockwave lithotripsy and endoscopic therapy for pancreatic stones. Clin Gastroenterol Hepatol 2005; 3:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/29\">",
"      Smits ME, Rauws EA, Tytgat GN, Huibregtse K. Endoscopic treatment of pancreatic stones in patients with chronic pancreatitis. Gastrointest Endosc 1996; 43:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/30\">",
"      Dumonceau JM, Devi&egrave;re J, Le Moine O, et al. Endoscopic pancreatic drainage in chronic pancreatitis associated with ductal stones: long-term results. Gastrointest Endosc 1996; 43:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/31\">",
"      Kozarek RA, Brandabur JJ, Ball TJ, et al. Clinical outcomes in patients who undergo extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. Gastrointest Endosc 2002; 56:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/32\">",
"      Farnbacher MJ, Schoen C, Rabenstein T, et al. Pancreatic duct stones in chronic pancreatitis: criteria for treatment intensity and success. Gastrointest Endosc 2002; 56:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/33\">",
"      Ammann RW, Akovbiantz A, Largiader F, Schueler G. Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology 1984; 86:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/34\">",
"      Seven G, Schreiner MA, Ross AS, et al. Long-term outcomes associated with pancreatic extracorporeal shock wave lithotripsy for chronic calcific pancreatitis. Gastrointest Endosc 2012; 75:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/35\">",
"      Dumonceau JM, Costamagna G, Tringali A, et al. Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: a randomised controlled trial. Gut 2007; 56:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/36\">",
"      Delhaye M, Arvanitakis M, Verset G, et al. Long-term clinical outcome after endoscopic pancreatic ductal drainage for patients with painful chronic pancreatitis. Clin Gastroenterol Hepatol 2004; 2:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/37\">",
"      Tandan M, Reddy DN, Santosh D, et al. Extracorporeal shock wave lithotripsy and endotherapy for pancreatic calculi-a large single center experience. Indian J Gastroenterol 2010; 29:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10168/abstract/38\">",
"      Gulbis B, Delhaye M, Vandermeeren A, et al. Biological markers of cell damage during shock wave lithotripsy: Evidence for a shock wave related granulocyte damage. J Stone Dis 1992; 4:34.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5658 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E421669322-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10168=[""].join("\n");
var outline_f9_59_10168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL SIGNIFICANCE OF PANCREATIC STONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LITHOTRIPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Stone localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Application of shock waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Need for ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Technical results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pain relief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pancreatic endocrine and exocrine function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Stone recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ESWL monotherapy compared to ESWL combined with endoscopic drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Need for surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5658|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/60/11213\" title=\"table 1\">",
"      ESWL technical results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/35/27197\" title=\"table 2\">",
"      ESWL clinical results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/47/44796\" title=\"table 3\">",
"      ESWL complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=related_link\">",
"      Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_59_10169="Leflunomide in the treatment of rheumatoid arthritis";
var content_f9_59_10169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Leflunomide in the treatment of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10169/contributors\">",
"     Robert Fox, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10169/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10169/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10169/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/59/10169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    (LEF) is an isoxazole derivative used for the treatment of rheumatoid arthritis (RA). LEF is structurally unrelated to other immunomodulatory disease-modifying antirheumatic drugs and offers a unique mechanism for the therapy of RA.",
"   </p>",
"   <p>",
"    LEF has also been effective in patients with psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/1\">",
"     1",
"    </a>",
"    ], juvenile polyarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/2\">",
"     2",
"    </a>",
"    ], refractory dermatomyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/3\">",
"     3",
"    </a>",
"    ], and systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/4\">",
"     4",
"    </a>",
"    ], but it has not been effective in ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     Teriflunomide",
"    </a>",
"    , the active metabolite of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , was found effective in patients with multiple sclerosis and is available for use in that condition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology of LEF, its immunologic effects, and its use in RA will be reviewed here. The general approach to the management of RA and the treatment of active disease are presented separately, as is the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    in patients with multiple sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H104685535#H104685535\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Teriflunomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MODE OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    (LEF) is an oral drug that is rapidly absorbed from the gastrointestinal tract. Once absorbed, LEF is converted to its active form, a malononitrilamide known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef56364 \" href=\"UTD.htm?31/43/32445\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/7\">",
"     7",
"    </a>",
"    ]. The major action of teriflunomide at the doses given for RA is inhibition of the synthesis of a pyrimidine known as ribonucleotide uridine monophosphate pyrimidine (rUMP).",
"   </p>",
"   <p>",
"    LEF decreases the synthesis of rUMP through inhibition of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). Inhibition of DHODH leads to inability of activated cells to move from G1 to the S phase by activating the p52 pathways of apoptotic selection. Additional mechanisms of action are listed below, but the inhibition of rUMP is thought to be the primary mechanism involved at the levels of drug reached in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The structure of the enzyme DHODH and the binding site for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    have been determined by x-ray crystallography [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/10\">",
"     10",
"    </a>",
"    ]. Human DHODH has two domains: an alpha-helical domain that forms the opening of a channel leading to the active site, and an",
"    <span class=\"nowrap\">",
"     alpha/beta-barrel",
"    </span>",
"    domain that contains the active site. Teriflunomide binds within the channel of the alpha-helical domain to exert its inhibitory effect on the enzyme.",
"   </p>",
"   <p>",
"    One study has suggested that polymorphisms in the estrogen receptor allele, estrogen receptor 1 (ESR1) may be associated with differences in efficacy among women treated with LEF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DOSE AND PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A loading dose of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days was used in some early clinical studies of LEF. However, use of a loading dose is associated with a higher likelihood of side effects, particularly diarrhea and other gastrointestinal disturbances. Thus, one of the authors (RF) and some experts prefer to begin LEF, starting at 20 mg per day, without a loading dose [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The other author (SH) and some experts prefer to use a loading dose of 100 mg daily for the first three days at the start of therapy or once weekly for three weeks while taking the regular daily dose on other days in an effort to more quickly reach a therapeutic effect.",
"   </p>",
"   <p>",
"    LEF is well-absorbed following oral administration. The serum half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    is approximately 15 days. Teriflunomide undergoes extensive enterohepatic recirculation.",
"   </p>",
"   <p>",
"    Drug elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    is achieved through the kidneys and gastrointestinal tract in an approximately equal ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/14\">",
"     14",
"    </a>",
"    ]. Teriflunomide is excreted in the urine as a glucuronide conjugate.",
"   </p>",
"   <p>",
"    Limited information is available concerning dosing in patients with renal or hepatic impairment. Results of single-dose studies in patients with chronic kidney disease indicate that LEF is not removed by continuous ambulatory peritoneal dialysis or by hemodialysis due to its high degree of protein binding [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in adults have not revealed differences in the pharmacokinetics of the drug based upon gender or age. However, clearance of LEF is increased 38 percent in smokers compared with non-smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma levels of the active metabolite above 0.02",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    may persist for up to two years and may carry a potential risk in pregnancy. If quick removal of LEF and its metabolites is required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine resin",
"    </a>",
"    is required because of the drug&rsquo;s enterohepatic recirculation.",
"   </p>",
"   <p>",
"    In some generic preparations of LEF used in Asia, contamination with commercial solvents has been detected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOLOGIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LEF has effects on many components of the immune-inflammatory response, some of which may be relevant to its mode of action in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukocyte adhesion &mdash; LEF inhibits leukocyte adhesion to vascular endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. This inhibition may be crucial during the &ldquo;homing&rdquo; of leukocytes to synovial high endothelial cells, which may occur early in the pathogenesis of RA [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/20-24\">",
"       20-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Memory T cells &mdash; LEF may have a preferential effect on self-reactive lymphocytes that comprise the memory cell population. Memory T cells have a greater tendency to undergo division arrest after restimulation with antigen than do lymphocytes undergoing a primary response [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/25\">",
"       25",
"      </a>",
"      ]. Thus, memory cells are more susceptible to DHODH inhibition.",
"     </li>",
"     <li>",
"      Dendritic cells &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      interferes with dendritic cell function, thereby leading to disruption of antigen presentation.",
"     </li>",
"     <li>",
"      Synovial inflammatory cells &mdash; The administration of either LEF or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      significantly decreases levels of synovial infiltration of lymphocytes and type I synoviocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/26\">",
"       26",
"      </a>",
"      ]. This decreased synovial infiltration of inflammatory cells is accompanied by reductions in markers of vascular inflammation and metalloproteinase production, perhaps explaining the decreased rate of radiographic progression [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nuclear factor (NF)-kappa B &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      blocks two steps essential for NF-kappa B activation: the degradation of the inhibitor of kappa B alpha and the subsequent translocation of the p65 subunit to the nucleus. These effects block the proinflammatory consequences of NF-kappa B activation in a dose- and time-dependent manner [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tyrosine kinases &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      inhibits protein tyrosine kinases Janus kinase (Jak)1 and Jak3 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/29\">",
"       29",
"      </a>",
"      ]. These kinases influence the stimulation of T cells through their interleukin (IL)-2 receptors.",
"     </li>",
"     <li>",
"      Interleukins &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      decreases the response to IL-4 by B cells, an effect that may augment the activity of hyaluronic acid synthetases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. Teriflunomide also inhibits IL-10 and IL-11 secretion and reduces the synthesis of IL-2 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transforming growth factor (TGF)-beta &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      may increase the synthesis of TGF-beta, a cytokine that exerts a dampening effect on the immune system in some settings [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      C-jun NH2-terminal protein kinase (JNK) &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      protected against",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (APAP) hepatotoxicity in an animal model by inhibiting APAP-induced activation of c-jun NH2-terminal protein kinase, JNK, thus preventing downstream Bcl-2 and Bcl-XL inactivation, mitochondrial permeabilization, and cytochrome c release [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other kinases &mdash; Inhibition of Janus kinase 3 (Jak3) and mitogen-activated protein kinase kinase kinase 2 (MAP3K2) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of potential adverse effects may occur. Observational studies indicate that cytochrome P450 (CYP1A2) and dihydroorotate dehydrogenase gene polymorphisms can influence the risk of adverse effects, but such testing is not available for routine clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    has been reported in some patients to potentiate the action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    as a result of its mutual competition at the level of cytochrome metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Theoretically, leflunomide administration in patients with cytochrome 2C9 polymorphisms might alter levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    in patients, as it has been noted to cause such changes at higher levels in rodent models [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/42\">",
"     42",
"    </a>",
"    ]. The major potential adverse effects of LEF are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small percentage of patients with RA develop hypertension when taking LEF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/43\">",
"     43",
"    </a>",
"    ]. Concurrent therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is a risk factor. The proposed mechanism is the displacement of NSAIDs from albumin by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    , thereby increasing NSAID activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/44\">",
"     44",
"    </a>",
"    ]. Blood pressure monitoring is recommended during the first months of treatment and is also recommended if NSAID therapy is begun at a later date. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea and nausea occur in 10 to 15 percent of patients taking LEF. These side effects are seldom severe enough to lead to drug discontinuation. Diarrhea may be more severe when a loading dose is used. [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Threefold elevation of serum aminotransferases have been noted in up to 13 percent of patients treated with LEF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Careful monitoring of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    has been thought to allow it to be used with a level of safety comparable to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/45\">",
"     45",
"    </a>",
"    ]. The changes in liver function are generally reversible with dose reduction or discontinuation of the drug. However, 49 cases of severe liver injury, including 14 cases of fatal liver failure, were reported to the US Food and Drug Administration (FDA) between August 2002 and May 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/46\">",
"     46",
"    </a>",
"    ]. Most patients who experience transaminase elevation have one or more comorbidities that might contribute to hepatotoxicity, including concomitant NSAID or MTX therapy, previous or concurrent alcohol abuse, or viral or autoimmune hepatitis. The FDA has issued a warning based upon these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of a practice-based cohort of 1953 patients with RA and 151 with psoriatic arthritis found that the risks of elevated hepatic aminotransferase levels above the upper limit of normal were greater with the combination of LEF and MTX compared with monotherapy with either agent or with the use of neither agent (31 percent versus 17 to 22 percent versus 14 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/47\">",
"     47",
"    </a>",
"    ]. Elevations of aminotransferase levels of greater than twice the upper limit of normal occurred in 1 to 2 percent of patients on LEF or MTX alone compared with 5 percent of patients on the combination. The risk appeared to be higher in patients with psoriatic arthritis and in those on higher doses of MTX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18582200\">",
"    <span class=\"h3\">",
"     Warnings and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving LEF should be closely monitored for signs of liver disease.",
"   </p>",
"   <p>",
"    The 2010 FDA warning based upon review of the cases of liver injury described above states [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with preexisting liver disease should not receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients with elevated liver enzymes (alanine aminotransferase [ALT] greater than two times the upper limit of normal) should not receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Caution should be used in patients who are taking other drugs that can cause liver injury.",
"     </li>",
"     <li>",
"      Liver enzymes should be monitored at least monthly for three months after starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      and at least quarterly thereafter.",
"     </li>",
"     <li>",
"      If the ALT rises to greater than two times the upper limit of normal while the patient is on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , leflunomide should be stopped,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      washout should be begun to speed the removal of leflunomide from the body, and follow-up liver function tests should be conducted at least weekly until the ALT value is within normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These FDA recommendations for monitoring frequency are consistent with those of the 2008 American College of Rheumatology (ACR) recommendations on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also advise, consistent with ACR guidelines, that patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and LEF concurrently be monitored monthly for one year, including serum albumin as well as aspartate and alanine aminotransferase levels, after which the monitoring interval may be increased to every two months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Leukopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of incidence in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    alone ranged from 1 in 3698 to 1 in 4582 patients exposed; for patients also taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , the estimates ranged from 1 in 575 to 1 in 822 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    treatment has been associated with an increased risk of interstitial lung disease. However, it is not clear whether this is a true effect or whether this is the result of &ldquo;channeling bias,&rdquo; in which patients with preexisting interstitial lung disease are more likely to be treated with LEF than with MTX, which is known to cause this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link&amp;anchor=H11#H11\">",
"     \"Drug-induced lung disease in rheumatoid arthritis\", section on 'Leflunomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy has been reported in patients receiving LEF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], with partial improvement after drug removal with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/53\">",
"     53",
"    </a>",
"    ]. A review of 80 cases reported to the United States Food and Drug Administration noted that symptoms of peripheral nerve dysfunction, typically characterized by axonal polyneuropathy, began a mean of six months after beginning the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/54\">",
"     54",
"    </a>",
"    ]. Discontinuation of LEF within 30 days of the onset of symptoms was associated with a better outcome than was discontinuation at a later time. In another study, 5 of 50 RA patients treated with LEF developed symptoms of peripheral neuropathy, but all improved after stopping the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, a case of aseptic meningitis that improved with drug removal has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rash and alopecia occur in 10 to 15 percent of patients taking LEF. These side effects are typically mild and seldom lead to drug discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hematology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic toxicity primarily results from an interaction between LEF and other drugs. LEF may enhance the bone marrow toxicity of MTX, possibly leading to pancytopenia, agranulocytosis, or thrombocytopenia.",
"   </p>",
"   <p>",
"    LEF can potentiate the anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/41\">",
"     41",
"    </a>",
"    ]. As a result, the international normalized ratio (INR) should be more carefully monitored after initiation of LEF in patients taking warfarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LEF is contraindicated in pregnant and nursing women and in patients with preexisting liver disease. (See",
"    <a class=\"local\" href=\"#H1257958\">",
"     'Pregnancy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Liver'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1257958\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If LEF is taken during pregnancy or if the patient becomes pregnant while taking LEF, elimination of the drug can be accelerated through the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    (8 grams orally three times daily for 11 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/8\">",
"     8",
"    </a>",
"    ]. Successful pregnancies have been reported in patients exposed to LEF before or during pregnancy. The risks of LEF use during conception, pregnancy, and lactation are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H19#H19\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Leflunomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     USE IN RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials have demonstrated the clinical efficacy of LEF as monotherapy for active RA. The principal drug with which LEF has been compared is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX).",
"   </p>",
"   <p>",
"    LEF is approved for both monotherapy of RA and for use in combination with MTX. In clinical practice, LEF is most commonly used in combination with MTX in patients who have had an inadequate response to MTX; who are not candidates for triple therapy with MTX,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ; and who are not eligible (often for reasons of insurance) to receive biologic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Comparison with MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major trials, one in the United States and one in Europe, have compared LEF with MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/8,56\">",
"     8,56",
"    </a>",
"    ]. Both of these trials have been criticized because of the relatively low maximum doses of MTX employed (up to 15",
"    <span class=\"nowrap\">",
"     mg/week).",
"    </span>",
"    The maximum dose of MTX for the treatment of RA is usually considered to be 20 to 25",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States study, 482 patients with active RA were randomly assigned to receive one of three treatment regimens for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LEF 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three days followed by 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      MTX 7.5",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      increasing to 15",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"     </li>",
"     <li>",
"      Placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LEF and MTX had similar times to initial response (8.6 versus 9.5 weeks).",
"     </li>",
"     <li>",
"      At one year, the efficacies of the two drugs were equivalent in terms of the frequency of responses equal to or greater than the ACR20 (52 versus 46 percent).",
"     </li>",
"     <li>",
"      Both LEF and MTX were superior to placebo in slowing radiographic progression of disease.",
"     </li>",
"     <li>",
"      Lack of efficacy was similar in the two treatment groups (17 versus 24 percent).",
"     </li>",
"     <li>",
"      Withdrawal for adverse effect was more common with LEF (22 percent versus 10 and 9 percent with MTX and placebo, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the major European trial, 999 patients with active RA were randomly assigned to receive either:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LEF (100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three days, followed by 20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"     </li>",
"     <li>",
"      MTX (10 to 15",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Outcome measures included both clinical and radiographic outcomes at one and two years. A subset of patients was followed for up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one year, the ACR20 response rate was significantly higher with the MTX group, although radiographic joint damage was similar for both treatments.",
"     </li>",
"     <li>",
"      At two years, there was no significant difference between the two groups either in synovitis or in the patient and clinician global assessments; however, radiographic progression was less with MTX.",
"     </li>",
"     <li>",
"      Twenty-one patients in the MTX group were withdrawn from their assigned treatment because of elevated serum aminotransferase concentrations. However, the patients were not provided with folate supplementation, the absence of which may have heightened MTX complications. Eight patients in the LEF group were withdrawn from their assigned treatment because of elevated serum aminotransaminase concentrations.",
"     </li>",
"     <li>",
"      At five years, more than 40 percent of the patients originally assigned to LEF remained clinically stable on that drug alone [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Comparison with sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a trial conducted in Europe, LEF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    achieved similar ACR20 responder rates (55 and 56 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/58\">",
"     58",
"    </a>",
"    ]. The two drugs continued to perform comparably at 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;LEF has been studied in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and tumor necrosis factor (TNF) inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     LEF and MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    and MTX is effective in patients who have not responded adequately to MTX alone. As an example, in a randomized, controlled trial of 263 patients, LEF or placebo was added to existing MTX therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/60\">",
"     60",
"    </a>",
"    ]. At 24 weeks, the proportion of patients who met ACR20 criteria for improvement was significantly higher with LEF compared with placebo (46 versus 20 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=see_link&amp;anchor=H11#H11\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\", section on 'Leflunomide and MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     LEF and cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open-label, randomized trial, 106 patients with active RA refractory to at least one disease-modifying antirheumatic drug (at least MTX) were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    LEF (20",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or both [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/61\">",
"     61",
"    </a>",
"    ]. Combination therapy was associated with significantly higher rates of both ACR50 (80 percent versus 40 and 42 percent) and ACR70 (69 percent versus 34 and 30 percent) responses compared with either drug alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     LEF and TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of a TNF inhibitor to LEF appears to benefit some patients; the degree of benefit may be comparable to that of a TNF inhibitor with MTX [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. An observational study using a population-based RA cohort of 1218 Swiss patients showed no difference in discontinuation rates, radiographic damage, functional disability, disease activity, or adverse events between patients who received a TNF inhibitor with MTX, LEF, or another nonbiologic disease-modifying antirheumatic drug (DMARD) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/64\">",
"     64",
"    </a>",
"    ]. Similar benefit with LEF was seen in a large German RA cohort as well [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/65\">",
"     65",
"    </a>",
"    ]. However, there are no randomized trials to demonstrate increased efficacy of LEF plus a TNF inhibitor compared with a TNF inhibitor alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10223860\">",
"    <span class=\"h3\">",
"     LEF and rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;One retrospective study of 77 patients with RA who had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus either LEF or MTX found comparable efficacy and safety with both combinations at six months following rituximab administration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10169/abstract/66\">",
"     66",
"    </a>",
"    ]. The majority of the patients receiving LEF had a history of MTX intolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      (LEF) is approved for both monotherapy and combination therapy (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) in the treatment of rheumatoid arthritis (RA).",
"     </li>",
"     <li>",
"      In clinical practice, LEF is most commonly used in RA patients who do not respond adequately to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) and who are not eligible for other treatment approaches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that the addition of LEF to MTX be considered in patients who are not candidates for triple therapy with MTX,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      and who are not eligible to receive biologic agents (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'LEF and MTX'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LEF achieves its antiinflammatory effects through the inhibition of a mitochondrial enzyme termed dihydroorotate dehydrogenase (DHODH), leading to a decrease in the synthesis of ribonucleotide uridine monophosphate pyrimidine (rUMP). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mode of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A starting dose of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of LEF is appropriate for most patients for whom LEF therapy is indicated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some experts but not others use a loading dose. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dose and pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LEF has a side effect profile comparable to that of MTX. The most common adverse effects, those related to the gastrointestinal tract, are minimized if no loading dose is used (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dose and pharmacokinetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Adverse effects'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      We advise monthly monitoring of liver function tests for the first three months of therapy, followed by testing at least every three months when LEF is used as a single agent. In patients who receive LEF in combination with MTX, liver function should be monitored monthly for at least the first year. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Liver'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/1\">",
"      Cuchacovich M, Soto L. Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002; 61:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/2\">",
"      Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/3\">",
"      Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008; 58:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/4\">",
"      Tam LS, Li EK, Wong CK, et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/5\">",
"      van Denderen JC, van der Paardt M, Nurmohamed MT, et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/6\">",
"      O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/7\">",
"      Panek JJ, Jezierska A, Mierzwicki K, et al. Molecular modeling study of leflunomide and its active metabolite analogues. J Chem Inf Model 2005; 45:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/8\">",
"      Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/9\">",
"      Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 1998; 53:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/10\">",
"      Liu S, Neidhardt EA, Grossman TH, et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 2000; 8:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/11\">",
"      Dziedziejko V, Kurzawski M, Safranow K, et al. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2011; 12:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/12\">",
"      Cohen SB, Iqbal I. Leflunomide. Int J Clin Pract 2003; 57:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/13\">",
"      Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003; :CD002047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/14\">",
"      Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/15\">",
"      Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999; 58:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/16\">",
"      Li J, Huang H, Zhang H. Detection of residual solvents in leflunomide by GC. Northwest Pharmaceutical Journal 2010; 1:003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/17\">",
"      Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997; 159:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/18\">",
"      Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996; 28:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/19\">",
"      Grisar J, Aringer M, K&ouml;ller MD, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004; 63:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/20\">",
"      Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997; 99:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/21\">",
"      Kraan MC, de Koster BM, Elferink JG, et al. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/22\">",
"      Kim JY, Yang MS, Oh CD, et al. Signalling pathway leading to an activation of mitogen-activated protein kinase by stimulating M3 muscarinic receptor. Biochem J 1999; 337 ( Pt 2):275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/23\">",
"      Kim KA, Kim S, Chang I, et al. IFN gamma/TNF alpha synergism in MHC class II induction: effect of nicotinamide on MHC class II expression but not on islet-cell apoptosis. Diabetologia 2002; 45:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/24\">",
"      Kim PH, Kagnoff MF. Transforming growth factor beta 1 increases IgA isotype switching at the clonal level. J Immunol 1990; 145:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/25\">",
"      Zhang X, Brunner T, Carter L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997; 185:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/26\">",
"      Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/27\">",
"      Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/28\">",
"      Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/29\">",
"      Siemasko K, Chong AS, J&auml;ck HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/30\">",
"      Burger D, Begu&eacute;-Pastor N, Benavent S, et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003; 42:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/31\">",
"      Gilbert C, Levasseur S, Desaulniers P, et al. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. J Immunol 2003; 170:5235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/32\">",
"      Stuhlmeier KM. Effects of leflunomide on hyaluronan synthases (HAS): NF-kappa B-independent suppression of IL-1-induced HAS1 transcription by leflunomide. J Immunol 2005; 174:7376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/33\">",
"      Vergne-Salle P, L&eacute;ger DY, Bertin P, et al. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 2005; 31:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/34\">",
"      Elkayam O, Yaron I, Shirazi I, et al. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003; 62:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/35\">",
"      Cao WW, Kao PN, Aoki Y, et al. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/36\">",
"      Latchoumycandane C, Goh CW, Ong MM, Boelsterli UA. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology 2007; 45:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/37\">",
"      Shaw J, Chen B, Wooley P, et al. A novel leflunomide analog, UTL-5b (GBL-5b), suppresses JAK3, MAP3K2, and LITAF genes. Am J Biomed Sci 2011; 3:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/38\">",
"      Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/39\">",
"      Grabar PB, Rozman B, Logar D, et al. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/40\">",
"      Chonlahan J, Halloran MA, Hammonds A. Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy 2006; 26:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/41\">",
"      Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002; 325:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/42\">",
"      Kirchheiner J, Brockm&ouml;ller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/43\">",
"      Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/44\">",
"      Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/45\">",
"      van Roon EN, Jansen TL, Houtman NM, et al. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide) www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm (Accessed on July 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/47\">",
"      Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/48\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     Reports of Leflunomide Hepatotoxicity in Patients with Rheumatoid Arthritis. file://www.rheumatology.org/publications/hotline/0801leflunomide.asp (Accessed on January 10, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/50\">",
"      Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/51\">",
"      Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 2004; 43:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/52\">",
"      Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007; 14:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/53\">",
"      Negi A, Rhys-Dillon C, Camilleri JP. A case of distal renal tubular acidosis (type 1) presenting with musculoskeletal pain. Rheumatology (Oxford) 2004; 43:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/54\">",
"      Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004; 75:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/55\">",
"      Cohen JD, Jorgensen C, Sany J. Leflunomide-induced aseptic meningitis. Joint Bone Spine 2004; 71:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/56\">",
"      Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/57\">",
"      Dayer JM, Cutolo M. Is there a rationale to using leflunomide in early rheumatoid arthritis? Clin Exp Rheumatol 2005; 23:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/58\">",
"      Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/59\">",
"      Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/60\">",
"      Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/61\">",
"      Karanikolas G, Charalambopoulos D, Andrianakos A, et al. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol 2006; 33:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/62\">",
"      Behrens F, Koehm M, Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Curr Opin Rheumatol 2011; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/63\">",
"      Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 2011; 23:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/64\">",
"      Finckh A, Dehler S, Gabay C, SCQM doctors. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009; 68:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/65\">",
"      Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10169/abstract/66\">",
"      Narv&aacute;ez J, D&iacute;az-Torn&eacute; C, Ruiz JM, et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2011; 41:401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7515 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10169=[""].join("\n");
var outline_f9_59_10169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MODE OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DOSE AND PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOLOGIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18582200\">",
"      - Warnings and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Leukopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hematology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1257958\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      USE IN RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Comparison with MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Comparison with sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - LEF and MTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - LEF and cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - LEF and TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10223860\">",
"      - LEF and rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7515|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/43/32445\" title=\"figure 1\">",
"      Activation of leflunomide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=related_link\">",
"      Drug-induced lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/98?source=related_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_59_10170="Gaucher disease: Treatment";
var content_f9_59_10170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gaucher disease: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10170/contributors\">",
"     Patrick Deegan, MD, MRCPI, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10170/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/59/10170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/59/10170/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/59/10170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. It results from deficiency of a lysosomal enzyme glucocerebrosidase (also known as glucosylceramide or acid beta-glucosidase, GBA). Glucosylceramide (also called glucocerebroside) and some related compounds, which ordinarily are degraded to glucose and lipid components by glucocerebrosidase, accumulate within the lysosomes of cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of GD is tailored to the individual patient, because of the variability in the manifestations, severity, and progression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. GD is one of the few inherited metabolic disorders for which enzyme replacement therapy is available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/4\">",
"     4",
"    </a>",
"    ]. Additional therapies include substrate reduction therapy and supportive care measures to manage associated conditions.",
"   </p>",
"   <p>",
"    The treatment of GD is discussed here. The pathogenesis, genetics, clinical manifestations, diagnosis, initial assessment, and routine monitoring are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THERAPEUTIC GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic goals of treatment are elimination or improvement of symptoms, prevention of irreversible damage, and improvement in the overall health and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. An additional goal in children is optimization of growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/6\">",
"     6",
"    </a>",
"    ]. An international panel of clinicians with extensive clinical experience in GD has developed a list of therapeutic goals to be used as guides for optimal treatment (",
"    <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5\">",
"     5",
"    </a>",
"    ]. Regular monitoring is performed to assess the response to therapy, make adjustments when goals are not met, and to ensure the maintenance of achieved goals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/6\">",
"     6",
"    </a>",
"    ]. The frequency of reevaluation depends upon disease severity and should be assessed on an individual basis (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visceral, hematologic, skeletal, and other aspects of nonneuronopathic disease are considered separately since each of these components is relatively independent of the others with respect to disease burden and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/6\">",
"     6",
"    </a>",
"    ]. Skeletal manifestations are associated with the greatest morbidity and, once present, are among the least responsive to enzyme replacement therapy (ERT). ERT may slow or prevent progression of skeletal complications, but osteonecrosis, osteosclerosis, and vertebral compression are irreversible. Early treatment may prevent or lessen the severity of these complications, and therefore, early identification is crucial to improving ultimate outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENZYME REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to offer enzyme replacement therapy (ERT) in nonneuronopathic GD is based upon disease severity, as determined by the initial assessment, or significant disease progression, as demonstrated through regular follow-up. ERT with recombinant glucocerebrosidases [",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    (Cerezyme) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8547?source=see_link\">",
"     velaglucerase alfa",
"    </a>",
"    (VPRIV)] is the preferred treatment for patients with clinically significant manifestations of nonneuronopathic GD (type 1 GD) and is also considered in neuronopathic GD (type 3, but not type 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5,10-14\">",
"     5,10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials conducted in the late 1980s and early 1990s demonstrated the efficacy of ERT in patients with type 1 Gaucher disease who were treated with glucocerebrosidase prepared from human placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The advance that was critical to the success of this technique was molecular targeting of the enzyme to tissue macrophages via mannose receptors expressed by these cells. A recombinant preparation has been available since 1993. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Preparation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The high cost of ERT (&gt;$400,000 per year for a 70 kg patient who receives 60",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/1\">",
"     1",
"    </a>",
"    ]) makes it necessary to define appropriate clinical indications for its use and to determine the lowest effective initial and maintenance doses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for treatment with ERT in children and adults have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5,8,9,17\">",
"     5,8,9,17",
"    </a>",
"    ]. These were developed by consensus of international experts, using data from the International Collaborative Gaucher Group Gaucher Registry.",
"   </p>",
"   <p>",
"    ERT is indicated for the following patients with",
"    <strong>",
"     nonneuronopathic",
"    </strong>",
"    (type 1) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9,18,19\">",
"     9,18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic children (including those with malnutrition, growth retardation, impaired psychomotor development,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fatigue) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/6,19\">",
"       6,19",
"      </a>",
"      ], since early presentation is associated with more severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with severe disease (eg, platelet count",
"      <span class=\"nowrap\">",
"       &lt;60,000/microL,",
"      </span>",
"      liver &gt;2.5 times normal size, spleen &gt;15 times normal size, radiologic evidence of skeletal disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The implementation of therapy and evaluation of response vary depending upon the initial assessment (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 2A-B",
"    </a>",
"    ) and individualized therapeutic goals (",
"    <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ERT also is used for individuals known to be at-risk for",
"    <strong>",
"     neuronopathic",
"    </strong>",
"    type 3 disease who present before the onset of neurologic symptoms (",
"    <a class=\"graphic graphic_table graphicRef50695 \" href=\"UTD.htm?18/37/19036\">",
"     table 3",
"    </a>",
"    ). ERT may stabilize the neurologic progression in some of these patients or be effective only on the somatic signs and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     Imiglucerase",
"    </a>",
"    (Cerezyme) is produced by recombinant DNA technology in a Chinese hamster ovary cell system and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8547?source=see_link\">",
"     velaglucerase alfa",
"    </a>",
"    (VPRIV) is produced by gene activation technology in a human cell line [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/12,13,20,21\">",
"     12,13,20,21",
"    </a>",
"    ]. The purified enzyme imiglucerase is a monomeric glycoprotein composed of 497 amino acids. Recombinant enzyme differs from the native form and the therapeutic placental form (alglucerase or Ceredase) by a His for Arg substitution at position 495 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/22\">",
"     22",
"    </a>",
"    ]. Alglucerase has been replaced by imiglucerase. Oligosaccharide chains at the glycosylation sites are modified by sequential deglycosylation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/23\">",
"     23",
"    </a>",
"    ] to terminate in mannose moieties. Mannose groups are specifically recognized by endocytic receptors, allowing uptake of the enzyme by the cell and trafficking to the lysosome. Velaglucerase differs from imiglucerase insomuch as the enzyme protein sequence is the native human sequence and greater mannose display is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large prospective trials comparing dose regimens have not been performed. Initial doses of 30 to 60",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    and 60",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    for velaglucerase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/12\">",
"     12",
"    </a>",
"    ], given every two weeks, were safe and effective in improving visceral and bone marrow disease and quality of life in patients with type 1 GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/12,16,24-26\">",
"     12,16,24-26",
"    </a>",
"    ]. Long-term outcomes of ERT with imiglucerase at two treatment centers using low-dose (median dose 15 to 30",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every four weeks) and high-dose (median dose 80",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every four weeks) treatment protocols in adult patients were compared retrospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/27\">",
"     27",
"    </a>",
"    ]. Improvement in hemoglobin, platelet count, and hepatosplenomegaly was not significantly different between cohorts. Patients at the center using high-dose ERT had more rapid improvement in plasma chitotriosidase (a marker of alternative type macrophage activation that is overexpressed in Gaucher cells) and bone marrow involvement as measured by magnetic resonance imaging (MRI). The improvements in these surrogate markers of disease activity are of unknown clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/28\">",
"     28",
"    </a>",
"    ], but they may provide some guidance for determining dose strategies, particularly in patients with severe bone marrow involvement.",
"   </p>",
"   <p>",
"    The initial dose is determined for the individual patient and depends upon age at presentation, comorbid conditions, the site(s) and extent of involvement, and the presence of irreversible pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5,19,29\">",
"     5,19,29",
"    </a>",
"    ]. The usual starting dose for patients with type 1 GD is between 30 and 60",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    administered intravenously over one to two hours every two weeks. The minimum recommended starting dose for children is 30",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"     9",
"    </a>",
"    ]. Progression of skeletal disease leading to irreversible skeletal damage has occurred in some patients treated with doses lower than 60",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every two weeks despite improvement in other parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/30\">",
"     30",
"    </a>",
"    ], but a formal assessment of dose response in skeletal disease has not yet been carried out.",
"   </p>",
"   <p>",
"    Young children may benefit from use of topical anesthetics prior to placement of the intravenous needle. Indwelling intravenous ports are generally not needed if the services of pediatric nurses skilled at peripheral IV placement are available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose adjustments are made on an individual basis. Dose increases may be necessary to achieve therapeutic goals, or for relapse following dose reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5\">",
"     5",
"    </a>",
"    ]. The dose should be increased by 50 percent if bone crises continue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/31\">",
"     31",
"    </a>",
"    ]. Generally patients with type 1 GD do not require more than 60",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every other week. An increased dose may also be indicated if visceromegaly, anemia, thrombocytopenia, and biomarkers fail to improve after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"     9",
"    </a>",
"    ]. However, an increased dose is unlikely to reverse certain types of pathology (ie, osteonecrosis and fibrosis of the liver, spleen, or lung). Additional evaluation may be necessary for patients who are unable to achieve their therapeutic goals after three to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Decisions regarding dose reduction should be made with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"     9",
"    </a>",
"    ]. Dose reductions should only be considered after all relevant therapeutic goals have been met [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5\">",
"     5",
"    </a>",
"    ]. Dose reductions should occur no more frequently than every six months and must be accompanied by reassessment of disease severity (",
"    <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"     table 1A-B",
"    </a>",
"    ) to ensure the maintenance of therapeutic goals (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 2A-B",
"    </a>",
"    ). The dose should not be reduced below 30",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every two weeks, according to pediatric recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean dose used for long-term therapy in the United States and Germany is approximately 30",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every two weeks (range 30 to 60",
"    <span class=\"nowrap\">",
"     Units/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/19\">",
"     19",
"    </a>",
"    ], but is lower in the United Kingdom, Netherlands, and Israel, for example (approximately 15",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    every other week, sometimes less) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is continued throughout the patient's life. Prolonged treatment interruptions are not recommended. There are several reports of disease progression during prolonged treatment interruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/32-38\">",
"     32-38",
"    </a>",
"    ]. Patients in whom interruptions of therapy are unavoidable require close monitoring during the time of discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5\">",
"     5",
"    </a>",
"    ]. Major problems in the production and supply of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    (Cerezyme) in 2009 and 2010 led to a six month shortage resulting in interruption of treatment and dose reduction. This six month interruption in treatment was associated with an increase in fatigue, generally modest falls in platelet count, increases in biomarkers, and occasional episodes of irreversible bone events [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nonneuronopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to treatment varies, but analysis of data from the Gaucher Registry demonstrates certain trends for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    and alglucerase in patients with nonneuronopathic (type 1) disease. Improvements usually occur within six months after initiation of therapy and include reduction of spleen and liver volume, resolution of thrombocytopenia and anemia, and reduction in fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/42\">",
"     42",
"    </a>",
"    ]. Skeletal improvement may not be evident until after two to three years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/16,19,43\">",
"     16,19,43",
"    </a>",
"    ]. Bone mineralization may stabilize and slowly improve, and the risk of pathologic fracture may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/44\">",
"     44",
"    </a>",
"    ]. Approximately one-quarter of patients still have thrombocytopenia (platelet count &lt;120 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L),",
"    </span>",
"    with severe persistent thrombocytopenia (platelet count &lt;60 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    seen in 2 percent of patients, after four to five years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/45\">",
"     45",
"    </a>",
"    ]. Predictors for persistent thrombocytopenia include very low baseline platelet count and increased baseline splenic volume.",
"   </p>",
"   <p>",
"    The original trial that led to licensing of alglucerase was an open-label, no comparator study in 12 subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/16\">",
"     16",
"    </a>",
"    ]. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have required subsequent agents (velaglucerase, taliglucerase) to undergo more extensive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/12,46,47\">",
"     12,46,47",
"    </a>",
"    ]. Not all studies are completed or published to date. Although there is limited direct and published evidence from head-to-head studies, preliminary evidence suggests to the author that all the aforementioned enzyme replacement therapies are approximately equivalent in efficacy.",
"   </p>",
"   <p>",
"    The effectiveness of ERT after two to five years of treatment was documented in 1028 patients (48 percent &lt;18 years old) in a report from the Gaucher Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/48\">",
"     48",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia &ndash; Hemoglobin concentrations typically increase to normal or near normal levels within 6 to 12 months, with a sustained response throughout five years.",
"     </li>",
"     <li>",
"      Thrombocytopenia &ndash; Patients with intact spleens usually have the greatest response within two years and have slower improvement thereafter. These patients have a smaller response if baseline thrombocytopenia is severe. Platelet counts return to normal in 6 to 12 months in the rare splenectomized patients with thrombocytopenia due to marrow failure.",
"     </li>",
"     <li>",
"      Visceral disease &ndash; Hepatomegaly and splenomegaly decrease by up to 60 percent, but spleen volume may remain more than five times normal in some patients.",
"     </li>",
"     <li>",
"      Skeletal disease &ndash;Symptoms resolved in 52 percent of patients with bone pain and no further episodes occurred in 94 percent of those who suffered bone crises before treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treating children with ERT may mitigate or prevent the complications that occur later in life, particularly skeletal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/6,31,49-51\">",
"     6,31,49-51",
"    </a>",
"    ]. Long-term ERT was associated with normalization or near normalization of height, hemoglobin, platelet count, liver and spleen volume, and bone mineral density among 884 children registered in the Gaucher Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/50\">",
"     50",
"    </a>",
"    ]. Improvement in the delayed onset of pubertal development is another potential benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and pooled analysis of observational studies of ERT (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    ) in adults found that the lumbar spine fat fraction approximately doubled compared with baseline measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/53\">",
"     53",
"    </a>",
"    ]. The percentage of responders to ERT based upon an increase in MRI T1-weighted signal and decrease in bone marrow infiltration ranged from 63 to 75 percent. The MRI bone marrow burden score also decreased after treatment (weighted mean difference, WMD -4.98; 95% CI [-8.38,-1.57]). However, there was not a significant increase in bone mineral density, as measured by lumbar spine and femur Z-scores, after ERT.",
"   </p>",
"   <p>",
"    A small open-label phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study of velaglucerase showed similar results to historical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    data [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/12,54\">",
"     12,54",
"    </a>",
"    ]. All five therapeutic goals (anemia, thrombocytopenia, hepatomegaly, splenomegaly, and skeletal pathology) were met in all patients (8 out of the original 12) who reached four years of treatment and were on a reduced dose for at least two years. No head-to-head studies of imiglucerase and velaglucerase have been performed, but therapeutic effects were comparable in a mouse model of GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neuronopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the use of ERT in patients with neuronopathic GD are less well established. The recombinant enzyme does not cross the blood brain barrier and therefore has limited ability to impact central nervous system disease. However, other somatic effects of GD should respond to ERT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In some studies, ERT was found to reverse almost all of the systemic manifestations and appeared to stabilize the neurologic disease (except progressive myoclonic epilepsy) in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. This was illustrated in a series of 21 patients, ages 8 months to 35 years, with type 3 GD who were treated with individually adjusted doses of enzyme and followed for two to eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement occurred in hemoglobin levels, platelet count, and acid phosphatase values.",
"     </li>",
"     <li>",
"      Spleen and liver volume decreased and bone structure improved.",
"     </li>",
"     <li>",
"      Asymptomatic interstitial lung disease, present in 19 patients, did not respond to treatment.",
"     </li>",
"     <li>",
"      Neurologic responses were variable:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Supranuclear gaze palsy was unchanged in 19 patients, improved in one, and worsened in one.",
"     </li>",
"     <li>",
"      Auditory brainstem response (ABR) improved or was unchanged in 19 patients and deteriorated in two. In another report, all eight children receiving high-dose ERT had deterioration in ABR [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive function was unchanged or improved in 13 patients and worsened in eight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ERT should be considered for patients with type 3 disease and severe visceral symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/18,56\">",
"     18,56",
"    </a>",
"    ]. In addition, it should be offered in patients at risk for type 3 neuronopathic GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/63\">",
"     63",
"    </a>",
"    ] due to genotype or family history who are identified early in the disease course before the onset of neurologic signs or symptoms. ERT may also have palliative effects on visceral manifestations in type 2 disease, but it does not alter the fatal neurologic outcome and therefore is generally not used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/57,64,65\">",
"     57,64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The European Working Group on Gaucher Disease has formulated consensus guidelines for the treatment of neuronopathic GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. These recommendations are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef50695 \" href=\"UTD.htm?18/37/19036\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     In pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/66\">",
"     66",
"    </a>",
"    ] and original data from several large treatment centers were summarized in a comprehensive review of ERT for Gaucher disease during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/67\">",
"     67",
"    </a>",
"    ]. Pregnancy in GD may be complicated by deterioration in hematologic disease, organomegaly, and bone involvement. Previously undiagnosed GD often comes to medical attention as a result. Data suggest a reduced risk of spontaneous abortion in women treated with alglucerase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    , and reduced risk of Gaucher-related complications during delivery and during the post partum period. The authors also concluded that there was no evidence of any untoward effects of alglucerase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imiglucerase on the fetus or on breastfed infants of treated mothers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring of disease activity should be carried out during ERT. Where possible, monitoring should be in accordance with at least the minimum recommendations for effective monitoring of patients provided by the ICGG (",
"    <a class=\"external\" href=\"file://gaucherregistry.com/\">",
"     gaucherregistry.com/",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/8\">",
"     8",
"    </a>",
"    ]. The recommended monitoring tests and schedule are discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are unable to achieve their therapeutic goals should undergo evaluation for confounding factors (eg, poor compliance with therapy, development of comorbid conditions, or development of neutralizing antibody). The additional evaluation varies depending upon the goal that is not achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     Imiglucerase",
"    </a>",
"    is generally well-tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/26,68\">",
"     26,68",
"    </a>",
"    ]. Adverse events due to treatment occur in approximately 10 percent of patients. The side effects are usually related to the IV infusion and include fever, chills, and flu-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/68\">",
"     68",
"    </a>",
"    ]. The mechanism is thought to be immune-related, but acute IgE-mediated reactions are very rare. When they occur, histamine-mediated symptoms may include pruritus, flushing,",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    chest discomfort, respiratory symptoms, cyanosis, and hypotension. ERT can be continued in most patients. In difficult cases, the infusion rate should be reduced and antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoids given before infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary hypertension may develop in patients who are receiving ERT, occurring in 12 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/69\">",
"     69",
"    </a>",
"    ], but this frequency has not been replicated on a wider international scale. It is not known whether this complication is caused by the enzyme infusion or the underlying disease. Patients with respiratory symptoms should be evaluated promptly with Doppler echocardiography to estimate right ventricular systolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 13 to 15 percent of treated patients develop IgG antibody to the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/18,68,70,71\">",
"     18,68,70,71",
"    </a>",
"    ]. Many of these patients stop producing antibody after two to three years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/70\">",
"     70",
"    </a>",
"    ]. The development of antibody may occasionally be associated with diminished effectiveness of ERT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. However, such events are infrequent. Thus, routine monitoring for the development IgG antibodies is not recommended. A pretreatment sample should be drawn and stored routinely and subsequent samples should be drawn and tested (in parallel with the stored baseline sample) if clinically indicated, for example, if infusion reactions occur or if there is a suspicion of diminished efficacy of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUBSTRATE REDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substrate reduction therapy (SRT) is an option in patients with type 1 GD who are unwilling or unable to receive ERT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/14,74,75\">",
"     14,74,75",
"    </a>",
"    ]. SRT reduces glycolipid accumulation by decreasing the synthesis of glucocerebroside, the substrate of the deficient enzyme.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     Miglustat",
"    </a>",
"    (N-butyldeoxynojirimycin, NB-DNJ, OGT-918, Zavesca), an inhibitor of glucosylceramide synthase, is approved in the United States for restricted use in adults with GD who are medically unable to receive ERT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/76\">",
"     76",
"    </a>",
"    ] and in Europe for symptomatic adult patients with mild to moderate disease in whom ERT is unsuitable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/10\">",
"     10",
"    </a>",
"    ]. The recommended dose is 100 mg three times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/77\">",
"     77",
"    </a>",
"    ]. It is also under investigation as a maintenance therapy for patients whose disease has stabilized during treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"     imiglucerase",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/78\">",
"     78",
"    </a>",
"    ]. Miglustat is contraindicated in pregnancy and in men wishing to start a family [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/79\">",
"     79",
"    </a>",
"    ]. Another oral formulation, eliglustat tartrate, is under development [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], with promising results in a phase II clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Phase III trials are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open-label study of 28 affected adults, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    (100 mg three times daily) for one year significantly decreased mean volumes of liver and spleen by 12 and 19 percent, respectively, with slight improvements in hemoglobin and platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/84\">",
"     84",
"    </a>",
"    ]. An open-label study using a lower dose of miglustat (50 mg three times daily) found smaller reductions in liver and spleen volume than with the larger dose, suggesting that the improvement in clinical features is dose dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/77\">",
"     77",
"    </a>",
"    ]. The incidence of side effects was similar to that in patients receiving the larger dose.",
"   </p>",
"   <p>",
"    A mean decrease in liver and spleen volumes (17 and 38 percent) and increase in mean hemoglobin levels (1.62",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    and platelet volume (40 percent) compared to baseline was seen in a phase II study of eliglustat tartrate (50 or 100 mg twice daily, based upon plasma drug concentrations) in 26 adult patients with GD1 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/82\">",
"     82",
"    </a>",
"    ]. Lumbar spine bone mineral density also increased and elevated biomarkers decreased after treatment. Side effects were mild and transient. Further improvements were seen two years after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study randomly assigned 36 patients who had received a minimum of two years of ERT to three groups: continued ERT, ERT plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    , and miglustat alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/74,78\">",
"     74,78",
"    </a>",
"    ]. Although patients in the miglustat group maintained visceral disease control, some patients had reductions in platelet count and increases in chitotriosidase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     Miglustat",
"    </a>",
"    crosses the blood-brain barrier and therefore may be beneficial in neuronopathic GD. However, in an open-label trial of ERT with or without concomitant miglustat, miglustat did not appear to have significant benefits on certain neurologic manifestations of type 3 GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     Miglustat",
"    </a>",
"    or related iminosugars could potentially benefit patients with other lipid-storage disorders including Niemann-Pick C and Tay-Sachs disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of treatment include diarrhea (79 percent of patients in one study), weight loss, tremor, and peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/74,84\">",
"     74,84",
"    </a>",
"    ]. These adverse effects are usually reversed by reducing the dose or discontinuing the drug; they also diminish with longer use. Gastrointestinal side effects may also improve with dietary modifications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antidiarrheal medications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER TREATMENT OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before ERT was available, splenectomy was performed to improve thrombocytopenia and anemia. Partial splenectomy sometimes was performed to minimize the risk of overwhelming sepsis with total splenectomy. However, partial splenectomy had limited success and was associated with serious complications, including accelerated bone destruction, regrowth of the splenic remnant with recurrence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/87\">",
"     87",
"    </a>",
"    ], and more rapid CNS deterioration in patients with type 3a (Norrbottnian) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/88\">",
"     88",
"    </a>",
"    ]. Total splenectomy was associated with a worse bone outcome than partial splenectomy in another series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/89\">",
"     89",
"    </a>",
"    ]. It is uncertain whether bony deterioration is a direct result of splenectomy, but one study has documented a strong temporal relationship between splenectomy and subsequent episodes of avascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of ERT has limited the indications for splenectomy. Splenectomy is indicated if other measures fail to control life-threatening thrombocytopenia with high risk of bleeding. Other possible indications include unremitting abdominal pain caused by recurrent splenic infarction, severe restrictive pulmonary disease, inferior vena cava syndrome, or inability to receive ERT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/87\">",
"     87",
"    </a>",
"    ]. Specific precautions must be taken to prevent sepsis in patients who require splenectomy. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) can provide a definitive cure for GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. However, this procedure is associated with substantial morbidity and mortality, and therefore has been effectively replaced by ERT in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. BMT is still considered in patients at risk for neuronopathic GD who present prior to the onset of neurologic signs or symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Future treatment of GD may include gene therapy. In an animal model, gene therapy through retroviral transduction of bone marrow from mice with type 1 GD both prevented the development of GD and corrected an established GD phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/95\">",
"     95",
"    </a>",
"    ]. In mice with established GD, gene therapy resulted in normalization of glucosylceramide concentrations and resolution of Gaucher cell infiltration of bone marrow, spleen, and liver five to six months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, retroviral vector transfer of the glucocerebrosidase gene into cultured bone marrow cells from Gaucher patients results in expression of physiologic levels of enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/96\">",
"     96",
"    </a>",
"    ]. However, efforts to accomplish this in the clinical setting have been unsuccessful because of the low efficiency of gene delivery into hematopoietic stem cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Enzyme enhancement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzyme enhancement therapy (EET), which attempts to increase the residual function of mutant enzymes, is another potential future therapy for GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/18\">",
"     18",
"    </a>",
"    ]. In EET, pharmacologic or chemical chaperones are used to stabilize folding of mutant glucocerebrosidase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/97-100\">",
"     97-100",
"    </a>",
"    ] or decrease its degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/101\">",
"     101",
"    </a>",
"    ]. Chemical chaperones for the treatment of GD have been evaluated in clinical trials, but the development program of the lead compound for Gaucher disease (afegostat tartrate, Plicera, Amicus Corp. NJ) was suspended as a result of lack of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care measures are necessary to manage bone disease, bleeding tendency, and other associated conditions (eg, parkinsonism). Management also includes addressing the psychosocial needs of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Skeletal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of bone disease is directed toward the prevention of irreversible complications, such as avascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possibility of osteomyelitis should be considered during episodes of bone pain, since delayed diagnosis of osteomyelitis is associated with increased morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/104\">",
"       104",
"      </a>",
"      ]. Blood cultures, imaging studies (ie, radionuclide scan, MRI)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone biopsies and cultures should be obtained as warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone pain crises can be ameliorated by intravenous fluids and analgesia. Options for analgesia include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and nonsteroidal antiinflammatory agents [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"       9",
"      </a>",
"      ]. Narcotics may be necessary for severe crises, but are not effective in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/105\">",
"       105",
"      </a>",
"      ]. Oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day) may be helpful in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       Alendronate",
"      </a>",
"      and other bisphosphonate drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/11\">",
"       11",
"      </a>",
"      ] may prove to be useful adjunctive therapy for adult patients whose osteopenia is refractory to ERT. In a controlled trial, patients who were treated with alendronate for 18 months had increased lumbar bone mineral density compared to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/106\">",
"       106",
"      </a>",
"      ]. Long bone radiographs showed no change in focal lesions or bone deformities in either group.",
"     </li>",
"     <li>",
"      Orthopedic procedures, such as hip replacement, may improve the quality of life. However, the success of these procedures may sometimes be limited by the cortical thinning that frequently is present. Four patients at one center had successful total hip replacement with uncemented components at least one year after onset of ERT [",
"      <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/107\">",
"       107",
"      </a>",
"      ]. The bone beyond the osteonecrotic areas was noted have a normal appearance and consistency at the time of surgery in these patients. These procedures should be undertaken at centers experienced with surgical management of metabolic bone disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Bleeding tendency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GD have an increased risk of bleeding because of thrombocytopenia, defective platelet function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coagulation factor abnormalities. They require appropriate evaluation and preparation before surgical procedures or pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link\">",
"     \"Preoperative assessment of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Neuronopathic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care will clearly be necessary for the neurologic disease in patients with type 2 or type 3 Gaucher disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/18\">",
"     18",
"    </a>",
"    ] This is usually best delivered under the care of an experienced (usually pediatric) neurologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link\">",
"     \"Aspiration due to swallowing dysfunction in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link\">",
"     \"Symptomatic (secondary) myoclonus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GD and clinical features of Parkinson disease are managed as other patients with PD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=see_link\">",
"     \"Nonpharmacologic management of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, patients with hematologic malignancies are normally referred to an oncologist or hematologist (see appropriate topic reviews on lymphoma, leukemia, and multiple myeloma).",
"   </p>",
"   <p>",
"    Patients with severe liver disease and hepatopulmonary syndrome may require liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/59/10170/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=see_link\">",
"     \"Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basic goals of treatment of Gaucher disease (GD) are elimination of symptoms, prevention of irreversible damage, and improvement in the overall health and quality of life. An additional goal in children is optimization of growth and development. Treatment of GD is tailored to the individual patient, because of the variability in the manifestations, severity, and progression of the disease. An international panel of clinicians with extensive clinical experience in GD has developed a list of therapeutic goals to be used as guides for optimal individualized treatment (",
"      <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Therapeutic goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to offer enzyme replacement therapy (ERT) in nonneuronopathic (type 1) GD is based upon disease severity, as determined by the initial assessment, or significant disease progression, as demonstrated through regular follow-up (",
"      <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"       table 2A-B",
"      </a>",
"      ). We recommend ERT with recombinant glucocerebrosidases (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"       imiglucerase",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8547?source=see_link\">",
"       velaglucerase alfa",
"      </a>",
"      ) for all symptomatic children and for patients with severe manifestations of nonneuronopathic (type 1) GD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonneuronopathic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest ERT for patients with neuronopathic type 3 disease and severe visceral symptoms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition, we suggest ERT in patients at risk for neuronopathic type 3 GD due to genotype or family history who are identified early in the disease course before the onset of neurologic signs or symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      administering ERT in patients with type 2 disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). ERT may have palliative effects on visceral manifestations in patients with type 2 disease, but it does not alter the fatal neurologic outcome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Neuronopathic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ERT is individualized. Factors considered in choosing the initial dose include age at presentation, comorbid conditions, the site(s) and extent of involvement, and the presence of irreversible pathology. For most patients, we use an initial dose of 30 to 60",
"      <span class=\"nowrap\">",
"       Units/kg",
"      </span>",
"      intravenously every two weeks; the minimum recommended starting dose for children is 30",
"      <span class=\"nowrap\">",
"       Units/kg.",
"      </span>",
"      Treatment response varies, but in general improvements occur within six months after initiation of therapy and include reduction of spleen and liver volume, resolution of thrombocytopenia and anemia, reduction in fatigue, and improvement in cardiac function. Improvement in skeletal disease may not be evident for two to three years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine monitoring of disease activity is performed during ERT (",
"      <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"       table 2A-B",
"      </a>",
"      ). Dose adjustments are made on an individual basis. We advise increasing the dose if visceromegaly, anemia, thrombocytopenia, and biomarkers fail to improve after six months, or if the patient fails to achieve specific therapeutic goals. We advise increasing the dose by 50 percent if bone crises continue. We suggest that dose reductions be considered only after all relevant therapeutic goals have been met. Dose reductions should occur no more frequently than every six months and must be accompanied by reassessment of disease severity to ensure the maintenance of therapeutic goals. Treatment is continued throughout the patient's life. Treatment interruptions are not recommended. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Administration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"       \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest substrate reduction therapy (SRT) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"       miglustat",
"      </a>",
"      , an inhibitor of glucosylceramide synthase, in patients with type 1 GD who are unwilling or unable to receive ERT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The recommended dose is 100 mg three times per day. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Substrate reduction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The availability and efficacy of ERT has limited the indications for splenectomy and hematopoietic cell transplantation. Splenectomy is indicated if other measures fail to control life-threatening thrombocytopenia. Bone marrow transplantation may be an option in patients known to be at-risk for neuronopathic disease who present early in the disease course. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Other treatment options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8644035\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author of this topic has the following disclosures that may be relevant to this topic: Speaker's Bureaus: Genzyme; Shire; Protalix (lysosomal diseases).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Beutler E, Grabowski GA. Gaucher disease. In: Metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.3635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/2\">",
"      Goker-Alpan O. Optimal therapy in Gaucher disease. Ther Clin Risk Manag 2010; 6:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/3\">",
"      Zimran A. How I treat Gaucher disease. Blood 2011; 118:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/4\">",
"      Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2010; 363:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/5\">",
"      Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/6\">",
"      Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/7\">",
"      Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA 1996; 275:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/8\">",
"      Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/9\">",
"      Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/10\">",
"      Cox TM, Aerts JM, Andria G, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003; 26:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/11\">",
"      Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008; 31:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/12\">",
"      Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010; 115:4651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/13\">",
"      Pastores GM. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs 2010; 11:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/14\">",
"      Martins AM, Valadares ER, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr 2009; 155:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/15\">",
"      Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 1990; 87:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/16\">",
"      Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/17\">",
"      Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/18\">",
"      Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/19\">",
"      Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/20\">",
"      Friedman B, Vaddi K, Preston C, et al. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 1999; 93:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/21\">",
"      Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010; 20:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/22\">",
"      Niederau C, vom Dahl S, H&auml;ussinger D. First long-term results of imiglucerase therapy of type 1 Gaucher disease. Eur J Med Res 1998; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/23\">",
"      Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981; 673:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/24\">",
"      Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993; 82:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/25\">",
"      Fallet S, Grace ME, Sibille A, et al. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatr Res 1992; 31:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/26\">",
"      Pastores GM. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs 2010; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/27\">",
"      de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006; 108:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/28\">",
"      Zimran A, Elstein D, Beutler E. Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease. Blood 2006; 108:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/29\">",
"      Hollak CE, Aerts JM, Goudsmit R, et al. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 1995; 345:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/30\">",
"      Migita M, Fukunaga Y, Ueda T, et al. Progression of bone disease without deterioration of hematological parameters in a child with Gaucher disease during low-dose glucocerebrosidase therapy. Nihon Ika Daigaku Zasshi 1994; 61:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/31\">",
"      Cohen IJ, Katz K, Kornreich L, et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 1998; 24:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/32\">",
"      Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 2000; 110:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/33\">",
"      Schwartz IV, Karam S, Ashton-Prolla P, et al. Effects of imilglucerase withdrawal on an adult with Gaucher disease. Br J Haematol 2001; 113:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/34\">",
"      vom Dahl S, Poll LW, H&auml;ussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001; 113:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/35\">",
"      Weinreb NJ. Interruption in enzyme replacement therapy for Gaucher disease. Br J Haematol 2001; 113:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/36\">",
"      T&oacute;th J, Erdos M, Mar&oacute;di L. Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003; 70:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/37\">",
"      Grinzaid KA, Geller E, Hanna SL, Elsas LJ 2nd. Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2002; 4:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/38\">",
"      Drelichman G, Ponce E, Basack N, et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007; 151:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/39\">",
"      Giraldo P, Ir&uacute;n P, Alfonso P, et al. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis 2011; 46:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/40\">",
"      Goldblatt J, Fletcher JM, McGill J, et al. Enzyme replacement therapy \"drug holiday\": results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis 2011; 46:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/41\">",
"      Zimran A, Altarescu G, Elstein D. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis 2011; 46:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/42\">",
"      Beutler E. Enzyme replacement therapy for Gaucher's disease. Baillieres Clin Haematol 1997; 10:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/43\">",
"      Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/44\">",
"      Ida H, Rennert OM, Kato S, et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 1999; 22:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/45\">",
"      Hollak CE, Belmatoug N, Cole JA, et al. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5&nbsp;years. Br J Haematol 2012; 158:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/46\">",
"      Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. PLoS One 2009; 4:e4792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/47\">",
"      Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011; 118:5767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/48\">",
"      Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002; 113:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/49\">",
"      Dweck A, Abrahamov A, Hadas-Halpern I, et al. Type I Gaucher disease in children with and without enzyme therapy. Pediatr Hematol Oncol 2002; 19:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/50\">",
"      Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008; 122:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/51\">",
"      Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 2011; 90:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/52\">",
"      Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000; 2:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/53\">",
"      Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis 2010; 33:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/54\">",
"      Elstein D, Cohn GM, Wang N, et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 2011; 46:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/55\">",
"      Xu YH, Sun Y, Barnes S, Grabowski GA. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 2010; 5:e10750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/56\">",
"      Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005; 17:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/57\">",
"      Prows CA, Sanchez N, Daugherty C, Grabowski GA. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997; 71:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/58\">",
"      Schiffmann R, Heyes MP, Aerts JM, et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 1997; 42:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/59\">",
"      Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001; 138:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/60\">",
"      Erikson A, Forsberg H, Nilsson M, et al. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 2006; 95:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/61\">",
"      Kraoua I, Sedel F, Caillaud C, et al. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain Dev 2011; 33:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/62\">",
"      Campbell PE, Harris CM, Vellodi A. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology 2004; 63:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/63\">",
"      Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/64\">",
"      Bove KE, Daugherty C, Grabowski GA. Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol 1995; 26:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/65\">",
"      Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009; 32:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/66\">",
"      Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 2004; 190:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/67\">",
"      Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009; 43:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/68\">",
"      Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007; 90:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/69\">",
"      Elstein D, Klutstein MW, Lahad A, et al. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 1998; 351:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/70\">",
"      Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999; 93:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/71\">",
"      Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993; 82:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/72\">",
"      Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood 1997; 90:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/73\">",
"      Brady RO, Murray GJ, Oliver KL, et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997; 100:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/74\">",
"      Zimran A, Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos Trans R Soc Lond B Biol Sci 2003; 358:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/75\">",
"      Moyses C. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci 2003; 358:955.",
"     </a>",
"    </li>",
"    <li>",
"     Zavesca&reg; (miglustat) package insert. Acetelion Ltd, San Francisco, CA, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/77\">",
"      Heitner R, Elstein D, Aerts J, et al. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002; 28:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/78\">",
"      Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007; 110:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/79\">",
"      Lachmann RH. Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs 2003; 4:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/80\">",
"      Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 2011; 51:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/81\">",
"      Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 2010; 11:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/82\">",
"      Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/83\">",
"      Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010; 116:4095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/84\">",
"      Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/85\">",
"      Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 2008; 64:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/86\">",
"      Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 2011; 34:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/87\">",
"      Zimran A, Elstein D, Schiffmann R, et al. Outcome of partial splenectomy for type I Gaucher disease. J Pediatr 1995; 126:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/88\">",
"      Kyllerman M, Conradi N, M&aring;nsson JE, et al. Rapidly progressive type III Gaucher disease: deterioration following partial splenectomy. Acta Paediatr Scand 1990; 79:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/89\">",
"      Fleshner PR, Aufses AH Jr, Grabowski GA, Elias R. A 27-year experience with splenectomy for Gaucher's disease. Am J Surg 1991; 161:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/90\">",
"      Ringd&eacute;n O, Groth CG, Erikson A, et al. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 1995; 59:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/91\">",
"      Erikson A, Groth CG, M&aring;nsson JE, et al. Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr Scand 1990; 79:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/92\">",
"      Rappeport JM, Ginns EI. Bone-marrow transplantation in severe Gaucher's disease. N Engl J Med 1984; 311:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/93\">",
"      Steward CG, Jarisch A. Haemopoietic stem cell transplantation for genetic disorders. Arch Dis Child 2005; 90:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/94\">",
"      Somaraju UR, Tadepalli K. Hematopoietic stem cell transplantation for Gaucher disease. Cochrane Database Syst Rev 2012; 7:CD006974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/95\">",
"      Enquist IB, Nilsson E, Ooka A, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A 2006; 103:13819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/96\">",
"      Fink JK, Correll PH, Perry LK, et al. Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc Natl Acad Sci U S A 1990; 87:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/97\">",
"      Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/98\">",
"      Sawkar AR, Cheng WC, Beutler E, et al. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 2002; 99:15428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/99\">",
"      Lin H, Sugimoto Y, Ohsaki Y, et al. N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta 2004; 1689:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/100\">",
"      Khanna R, Benjamin ER, Pellegrino L, et al. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J 2010; 277:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/101\">",
"      Lu J, Yang C, Chen M, et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A 2011; 108:21200.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.gaucher.org.uk/enews.php?id=303 (Accessed on December 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/103\">",
"      Packman W, Crosbie TW, Behnken M, et al. Living with Gaucher disease: Emotional health, psychosocial needs and concerns of individuals with Gaucher disease. Am J Med Genet A 2010; 152A:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/104\">",
"      Bell RS, Mankin HJ, Doppelt SH. Osteomyelitis in Gaucher disease. J Bone Joint Surg Am 1986; 68:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/105\">",
"      Cohen IJ, Kornreich L, Mekhmandarov S, et al. Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. Arch Dis Child 1996; 75:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/106\">",
"      Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004; 104:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/107\">",
"      Bubbar V, Heras FL, Amato D, et al. Total hip replacement in Gaucher's disease: effects of enzyme replacement therapy. J Bone Joint Surg Br 2009; 91:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/108\">",
"      Lachmann RH, Wight DG, Lomas DJ, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000; 93:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/59/10170/abstract/109\">",
"      Ayto RM, Hughes DA, Jeevaratnam P, et al. Long-term outcomes of liver transplantation in type 1 Gaucher disease. Am J Transplant 2010; 10:1934.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2934 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-F0872C54B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10170=[""].join("\n");
var outline_f9_59_10170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THERAPEUTIC GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENZYME REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Initiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nonneuronopathic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neuronopathic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - In pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUBSTRATE REDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Enzyme enhancement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Skeletal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Bleeding tendency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Neuronopathic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8644035\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2934|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/55/43900\" title=\"table 1A\">",
"      Gaucher treatment goals A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/7/121\" title=\"table 1B\">",
"      Gaucher treatment goals B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/43/23229\" title=\"table 2A\">",
"      Monitoring type1 GD A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/35/10813\" title=\"table 2B\">",
"      Monitoring type1 GD B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/37/19036\" title=\"table 3\">",
"      Treatment of neuronopathic GD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=related_link\">",
"      Gaucher disease: Initial assessment, monitoring, and clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=related_link\">",
"      Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=related_link\">",
"      Nonpharmacologic management of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=related_link\">",
"      Overview of Niemann-Pick disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_59_10171="Max doses PCNs in renal failure";
var content_f9_59_10171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjusted maximum dose of newer penicillins in renal disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        GFR (mL/min)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Removal by dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &gt;50",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-50",
"       </td>",
"       <td class=\"subtitle2\">",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticarcillin",
"       </td>",
"       <td>",
"        3g Q4h",
"       </td>",
"       <td>",
"        3g Q6h",
"       </td>",
"       <td>",
"        2g Q12h",
"       </td>",
"       <td>",
"        Yes (H, P)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperacillin",
"       </td>",
"       <td>",
"        4g Q6h",
"       </td>",
"       <td>",
"        4g Q8h",
"       </td>",
"       <td>",
"        4g Q12h",
"       </td>",
"       <td>",
"        Yes (H), No (P)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H: hemodialysis; P: peritoneal dialysis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10171=[""].join("\n");
var outline_f9_59_10171=null;
var title_f9_59_10172="Causes of hypokalemia";
var content_f9_59_10172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypokalemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased potassium intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased entry into cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An elevation in extracellular pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased availability of insulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated &beta;-adrenergic activity - stress or administration of beta agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemic periodic paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marked increase in blood cell production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloroquine intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased gastrointestinal losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tube drainage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laxative abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased urinary losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary mineralocorticoid excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of gastric secretions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonreabsorbable anions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal tubular acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypomagnesemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salt-wasting nephropathies - including Bartter's or Gitelman's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased sweat losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Plasmapheresis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10172=[""].join("\n");
var outline_f9_59_10172=null;
var title_f9_59_10173="Sarcoid monitoring";
var content_f9_59_10173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring disease activity in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients with active disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Every 3 to 4 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ROS including fever, fatigue, weight loss, visual disturbance, dyspnea, cough, palpitations, abdominal pain, numbness, tingling, lightheadedness, syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PE including skin exam, palpation of lymph nodes, lung exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lab tests based on sites of disease activity and medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spirometry, diffusing capacity, ambulatory oximetry (or 6 minute walk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Every 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ophthalmologic exam, if on hydroxychloroquine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CBC and differential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AST, ALT, Alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25 hydroxy vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1,25 dihydroxy vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ACE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        EKG, sooner if palpitations, lightheadedness, syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ophthalmologic exam (slit lamp, fundoscopic, tonometric), sooner if visual disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        As indicated by symptoms or other tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HRCT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Holter monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ACE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSH (association of thyroid autoimmunity and sarcoidosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone density when glucocorticoid therapy initiated and then every 3 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI with gadolinium if neurologic symptoms (unless diabetic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients with inactive disease for 2 or more (?) years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Every 12 to 18 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ROS including fever, fatigue, weight loss, visual disturbance, dyspnea, cough, palpitations, abdominal pain, numbness, tingling, lightheadedness, syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PE including skin exam, palpation of lymph nodes, lung exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spirometry, diffusing capacity, ambulatory oximetry (or 6 minute walk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CBC and differential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1,25 dihydroxy vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        EKG, sooner if palpitations, lightheadedness, syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ophthalmologic exam, sooner if visual disturbance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ROS: review of systems; PE: physical exam; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ACE: angiotensin converting enzyme; EKG: electrocardiogram; HRCT: high resolution computed tomography; TSH: thyroid stimulating hormone; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10173=[""].join("\n");
var outline_f9_59_10173=null;
var title_f9_59_10174="ST segment resolution and mortality";
var content_f9_59_10174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mortality after thrombolytic therapy is lower with complete ST segment resolution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In four studies of thrombolytic therapy for an acute myocardial infarction, the degree of ST segment resolution at 180 min after administration of therapy was associated with 35-day mortality. All studies found statistically significant mortality differences between the three groups of ST resolution.",
"    <div class=\"footnotes\">",
"     GUSTO-III: Global Use of Strategies to Open Occluded Coronary Arteries study; HIT-4: Hirudin for Improvement of Thrombolysis (HIT)-4 study; INJECT: International Joint Efficacy Comparison of Thrombolytics study; ISAM: Intravenous Streptokinase in Acute Myocardial Infarction.",
"    </div>",
"    <div class=\"reference\">",
"     Data from de Lemos JA, Braunwald E. J Am Coll Cardiol 2001; 38:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10174=[""].join("\n");
var outline_f9_59_10174=null;
var title_f9_59_10175="Mainstem bronchus mass CT";
var content_f9_59_10175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T3 lung cancer near carina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan in a patient with bronchogenic carcinoma shows a central mass encasing the right mainstem bronchus (large arrow), in close proximity to the carina. There are also speckled calcifications in the hilar mass and in subcarinal nodes (small arrow) from previous granulomatous disease. The location of this hilar mass is consistent with a T3 tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_59_10175=[""].join("\n");
var outline_f9_59_10175=null;
